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Background: Prenatal detection of congenital anomalies has forced Maternal Fetal
Medicine specialists (MFMs) to navigate many new ethical and legal issues when
counseling expecting parents. And yet, little is known about the attitudes, beliefs and
perceptions of MFMs regarding the intersection of prenatal diagnosis, disability and
termination. Thus, we aimed to identify the key attitudes and opinions surrounding prenatal
genetic testing, disability and termination of MFM specialists who counsel expectant
mothers with a prenatal diagnosis of fetal anomaly.
Methods: This was a prospective, qualitative study using semi-structured interviews with
MFMs across the nation, recruited through the snow-ball method. Interviews were audiorecorded, transcribed, and qualitatively analyzed using modified grounded theory by three
reviewers.
Results: 2,227 codes from 17 interviews were grouped into six clusters. Codes were then
characterized to triangulate MFM perspectives into 18 themes and 39 sub-themes.
Difficulties with patient misunderstanding of prenatal genetic screening, diagnostic
technology, the implications of certain genetic anomalies, and limited time to explain these

factors were identified as major barriers to effective counseling. All physicians reported
viewing themselves primarily as informants in the prenatal diagnostic process, and all
offered their patients the option of termination in the case of the diagnosis of a severe or
lethal congenital anomaly; however, physician definitions of severe or lethal congenital
anomaly differed. Moreover, physicians reported fears of being perceived as coercive by
patients, and a high degree of moral and emotional distress during these consultations.
Finally, physicians identified legal, financial and structural barriers that prevented patients
from accessing prenatal genetic diagnostic services and termination services. It was felt
that these limitations ultimately inhibited autonomous decision making by patients.
Conclusions: These findings highlight important barriers, perspectives, and conflicts that
occur for MFM providers during prenatal consults with pregnant women following prenatal
discovery of congenital anomalies. Further exploration of the identified themes in this
study would benefit MFM providers in identifying strategies to improve prenatal
counseling.
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INTRODUCTION
Recent and rapidly developing advances in the world of prenatal screening and diagnosis
have given future parents access to the genetic makeup of their fetus earlier in gestation
than ever before. The scope of each of these tools is increasing, allowing us to more
accurately identify anomalous genetic conditions. The choice of which testing modality to
use is patient specific, and dependent in large part on both the gestational age of the fetus
in question and the level of detail regarding the fetus’ genetic makeup that the family is
seeking.

For a subset of patients, what starts off as a simple prenatal screening blood test or
ultrasound can quickly evolve into an ethical minefield of decisions on further prenatal
genetic testing and pregnancy continuation versus termination in the event that a congenital
anomaly is identified. And while Maternal Fetal Medicine specialists (MFMs) remain the
primary point of contact for families navigating the complexities of this decision-making
process, typically after a referral from their primary obstetric provider, little work has been
done to understand their viewpoints on issues surrounding prenatal genetic testing,
disability in the setting of congenital or genetic anomaly and pregnancy termination
following a diagnosis of congenital anomaly. As such, we sought to explore the ethical
pitfalls of our current prenatal genetic testing paradigm, the role of MFMs in that paradigm,
and MFM perceptions on where this current paradigm both fails and succeeds in ensuring
optimal patient care. Ultimately, we hope our findings can be leveraged to improve the
delivery of care for patients receiving prenatal genetic testing.
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Prenatal Genetic Screening and Diagnosis
In general, the purpose of prenatal genetic testing is to identify chromosomal abnormalities.
Indeed, chromosomal abnormalities in pregnancy are relatively common, with
approximately 1 in 150 live births involving some type of chromosomal abnormality1.
While the most common chromosomal abnormality remains aneuploidy, there are a
number of chromosomal anomalies to consider. Specifically, aberrations in chromosomal
structure, which include deletions, duplications, translocations, and other rearrangements.
Of note, these aberrations are not necessarily pathologic. For example, chromosomal
translocations can be balanced. This means that the normal genomic content is preserved
but rearranged. Additionally, chromosomal anomalies are not necessarily present in all
fetal cells. When this occurs, the fetus is said to be mosaic, and it can lead to variable
phenotypes in the neonate2 .

Clearly, prenatal diagnosis can be incredibly complex, and a diagnosis made via prenatal
genetic testing is not always sufficient to predict the clinical outcome of the fetus. That
being said, prenatal genetic testing remains the primary method through which parents
concerned about the presence of aneuploidy in their fetus can learn more about their fetus’
genetic makeup. At present, primary testing options offered to expectant mothers are
divided into two major categories: screening tests and diagnostic tests. Understanding the
difference between these two forms of testing is critical, as screening tests are designed to
assess whether a patient is at increased risk of having a fetus affected by a genetic disorder.
Diagnostic tests, on the other hand, are intended to determine whether a specific genetic
disorder or condition is present in the fetus2. Consequently, a clear understanding of the
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way these tests work, and how they are incorporated into current practice, are critical to
any discussion on their utility.

Current primary screening options include the first trimester screen, the second trimester
screen and cell free DNA testing (cfDNA), also referred to as Non-invasive Prenatal
Testing (NIPT) in the literature. Prior to the development of NIPT, obstetric providers
could offer their patients a first trimester screen, the second trimester screen, or a
combination of the two screens through sequential or contingent screening. Factors
included in these screening options include nuchal translucency ultrasound, serum levels
of beta-hCG, Pregnancy-Associated Plasma Protein A (PAPP-A), Alpha Fetoprotein
(AFP), Estriol and Inhibin. These screening modalities integrate various components
including the patient’s age, race, presence of pregestational diabetes and multiple
gestations in order to provide the patient with a risk calculation for the presence of fetal
trisomy 21, 18, or 13. Of these, the most common chromosomal disorder is trisomy 21,
with an incidence of about 1 in 700 live births3. While trisomy 18 and 13 are rarer, with
incidences of 1 in 3,3153 and 1 in 7,4093 live births respectively, screening for these
conditions is desirable to many women given their life-limiting nature4.

Use of the first and second trimester screens has decreased in favor of NIPT. While the
extent to which NIPT has been adopted among women in the United States is not clear,
one study estimates that 25-50% of all pregnant women in the United States receive NIPT5.
NIPT screens for fetal aneuploidies using the analysis of cfDNA fragments in the maternal
circulation. The fetal component of cfDNA originates from placental trophoblasts released
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into maternal circulation from cells undergoing programmed cell death. As such, the
quantity of cfDNA from the fetus increases throughout gestation. At present, NIPT is the
most sensitive and specific screening test for the common fetal aneuploidies. However, it
has the potential for false positive and false negative results, and is not equivalent to
diagnostic testing6. Performance of NIPT in patients who receive an interpretable result is
shown in Table 1.

Sensitivity (%) Specificity (%)

Age 25 Years

Age 40 Years

PPV (%)

PPV (%)

Trisomy 21

99.3

99.8

33

87

Trisomy 18

97.4

99.8

13

68

Trisomy 13

91.6

99.9

9

57

Sex Chromosome

91.0

99.6

20-40%

20-40%

Aneuploidy
Table 1. Performance of NIPT in detection of trisomies 21, 18, 13 and sex chromosome
aneuploidies, adapted from ACOG Committee Opinion No. 6407. The Positive Predictive Value
(PPV) of these tests describes the probability that subjects with a positive screening test truly have
the disease and varies based on patient age.

Diagnostic tests are able to diagnose the presence of a genetic disorder in a fetus with
certainty. Each of these tests is done at a different stage of gestation, and comes with their
own risks and benefits. Diagnostic testing is most commonly performed during pregnancy
with fetal cells obtained by amniocentesis or placental cells from chorionic villus sampling
(CVS). Patients undergoing in vitro fertilization can also have preimplantation genetic
testing performed on cells from their pre-implanted embryo. Preimplantation genetic
diagnosis involves the testing of an embryo created via in-vitro fertilization prior to
implantation. This mode of diagnosis is generally used to test for a genetic condition in
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which a specific mutation has been identified in the family, but can also be used to screen
for genetic anomaly in instances where there is no known familial history of mutation.
Because this method of diagnosis requires only a few cells from the early embryo, errors
in diagnosis are possible, with one study reporting misdiagnosis following preimplantation
genetic testing to occur in less than 1 in 200 pregnancies8. Thus, confirmation of these
results via CVS or amniocentesis later in gestation is recommended2.

CVS is performed as early as 10 weeks gestation. Through this method, placental villi are
obtained for genetic analysis. Placental villi are acquired through either a transcervical or
transabdominal approach, as limited data has shown there is no significant difference in
risk between either approach9. With ultrasound guidance, the tip of a needle or specialized
catheter is placed into the placenta without entering the amniotic sac. Negative pressure
with a syringe is then used to aspirate a small amount of placental villi2. The main
advantage to this method remains how early in gestation it can be performed, with results
taking anywhere from 24 hours – 14 days to return. Consequently, expectant mothers might
have the results of their CVS test returned within their first trimester. This, in turn, allows
for more management options available to women with an abnormal result regarding
pregnancy continuation or termination. Complications of CVS include minor risks, such as
vaginal spotting, and more significant risks, such as pregnancy loss, limb reduction defects,
heavy vaginal bleeding, culture failure, amniotic fluid leakage and infection. However, the
actual risk of any of these complications, with the exception of vaginal spotting or bleeding,
is less than 1% in patients that have a transabdominal approach2. In contrast, up to 32% of
patients who undergo CVS via transcervical approach may experience vaginal spotting or
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bleeding . Thus, CVS proves to be a safe method of genetic testing and diagnosis early in
gestation. Of note, mosaicism is more likely to be found in CVS samples due to cases of
confined placental mosaicism. If identified, amniocentesis is typically offered to assess
whether mosaicism is present in fetal cells as well. In 90% of cases, the amniocentesis
result is normal, giving the diagnosis of confined placental mosaicism11.

Figure 1. A visual representation of the prenatal genetic testing timeline by gestational age in
weeks. Preimplantation genetic diagnosis takes place prior to the start of a pregnancy. The
remaining tests can be done at the end of the first trimester through the remainder of the pregnancy.

Amniocentesis is generally performed between 15 weeks and 20 weeks of gestation.
Performance of amniocentesis prior to 15 weeks of gestation is not recommended as it
results in significantly higher rates of pregnancy loss2. Amniocentesis is performed with
ultrasound guidance, and requires a 22-gauge spinal needle to obtain a sample of 20-30 mL
of amniotic fluid. The most significant risk of this procedure remains pregnancy loss,
however, the actual rate of loss as a result of amniocentesis remains under 1%12.
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Thus, while it is clear patients have access to a variety of screening and diagnostic genetic
tests, the method they ultimately choose is influenced by a number of factors. These
include, but are not limited to, the time of presentation for prenatal care, personal and
family history of chromosomal abnormalities, maternal age, and concerning findings on a
screening ultrasound. As such, expectant mothers may receive both a screening and
diagnostic genetic test, a screening ultrasound and a diagnostic genetic test, or even just a
screening genetic test. The combination of tests an expecting mother chooses to undergo
is extremely personal, and is decided in large part through discussions with their OBGYN.

The Reproductive Autonomy Rationale as an Ethical Framework for Prenatal
Diagnosis
In general, the purpose of a prenatal genetic screening test lies in its ability to provide an
assessment of a patient’s risk of carrying a fetus with a chromosomal disorder.
Consequently, the current recommendation from the American College of Obstetricians
and Gynecologists (ACOG) is that prenatal genetic screening should be discussed with and
offered to all pregnant women regardless of maternal age or risk of chromosomal
abnormality, as all women should have the right to the knowledge that prenatal testing
provides6.

This recommendation is in line with the “reproductive autonomy rationale,” which is
rooted in the idea that women should make informed decisions surrounding their
pregnancy. According to this ideology, access to prenatal testing promotes a woman’s
ability to make informed choices by empowering them to manage their pregnancies in a
way that aligns with their preferences and personal value system. This rationale emphasizes
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nondirective counseling and consent as the primary means by which women’s decisions
about testing and subsequent care are informed and free of undue pressure13.

Respect for patient autonomy is considered to be the foundation of modern Western
biomedical ethics. Beauchamp and Childress, in their “Principles of Biomedical Ethics,”
define respect for autonomy as a “professional obligation…[and] autonomous choice [as]
a right, not a duty, of patients”14. Integral to autonomous choice is the “respectful treatment
in disclosing information”14. Indeed, the primary justification for informed consent in our
current ethical model has been to protect autonomous choice. To that end, Beauchamp and
Childress have recommended a model for informed choice. As part of this model, they
define three major categories: Threshold Elements, or preconditions for informed consent;
Information Elements; and Consent Elements. Within each major category, they further
define subcategories. In order to meet the preconditions of informed consent, a patient must
be considered competent and possess voluntariness to make a decision. In order to
successfully complete the Information Elements of informed consent, a physician must: 1)
disclose material information; 2) recommend a plan; and 3) ensure the patient has
understood the information provided. Finally, in order to complete the Consent Elements
of informed consent, a patient must make a decision in favor for or against a given plan,
and authorize said plan14.

For the purposes of this discussion, I will focus on the Information Elements of this
construct, as it is often presented as the sole focus of informed consent. To fulfill this
element, patients must be given “facts or descriptions that patients or subjects usually
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consider material in deciding whether to refuse or consent to the proposed intervention .”
Additionally, they must “understand at least what a health care professional...believes a
patient...needs to understand in order to authorize [said intervention]14.”

To fulfill these requirements of informed consent professional bodies have published
extensive guidelines that outline the necessary practical steps for clinicians to follow. For
example, ACOG recommends that patients should be given access to high quality, accurate
information about the technology of the testing modality in question and their results. This
includes information surrounding the detection and false positive rates, advantages,
disadvantages and limitations of screening tests as well as the risks and benefits of
diagnostic procedures6. Second, patients should be given information surrounding life with
any of the anomalies being screened for, and implications of a positive result. Finally,
patients should be given adequate time to discuss prenatal testing with their providers in
order to ensure full understanding.

The fact that fulfillment of these standards must be met and documented prior to any
medical procedure ensures that women understand that invasive prenatal diagnostic testing
is associated with an increased risk of miscarriage. Noninvasive screening tests, on the
other hand, have proven to be a challenge as they do not have a procedural timepoint to
mark the need for informed consent. Thus, since its inception, an “extensive gap between
theory and practice when it comes to informed consent” has existed for NIPT13. Indeed, a
meta-analysis of thirty empirical qualitative research studies found that women
consistently expressed dissatisfaction with the quality and quantity of information provided
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to them during counselling on NIPT. Specifically, these women identified three major areas
where the counseling they received was lacking. First, they reported that they did not feel
their clinician was sufficiently informed about the technology to facilitate informed choice.
They felt this gap in knowledge was especially pronounced when discussing the experience
of raising a child with conditions such as trisomies 13 and 18 and sex-linked disorders.
Second, appointment time constraints contributed to an overall sense of dissatisfaction with
counseling received, with women reporting that consultations were too short for adequate
counseling to be delivered. Finally, and especially concerning, when asked to describe
NIPT, many women described it as easy or just another blood test15.

These findings highlight further detractors from informed decision making, including
routinization or a pressure to test15. Moreover, each of the above identified barriers to
informed consent serves as a direct threat to the reproductive autonomy rationale, and
warrants further discussion.

Gaps in Provider Knowledge Surrounding NIPT Technology
Patients receiving counseling by their healthcare providers on NIPT have raised concerns
that health care providers have not been able to provide adequate information to patients
in order for them to make a fully informed decision regarding NIPT during their
pregnancy15. This may be a result of the rapid diffusion and widespread implementation of
NIPT. Thus, it is imperative that we understand the difficulties faced by healthcare
providers seeking to interpret and explain NIPT to patients.
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Pragmatic issues, in particular how the results of NIPT are reported, provide a partial
explanation for why providers struggle to counsel women appropriately on the results they
can expect from NIPT, and the implications of these results. While NIPT screens for three
common aneuploidies and sex chromosome abnormalities, the results of this screen are not
reported in a simple, bimodal fashion--in other words, physicians do not receive a printout detailing the aneuploidies screened for with a “positive” or “negative” result to indicate
the presence or absence of aneuploidy in the fetus. Because NIPT is a non-definitive
screening test performed by a number of different companies, results can be reported as
positive, “high risk,” negative, “low risk,” or some variation of “no call,” without any
concrete calculations to qualify these predictions. This stands in stark contrast to the
manner in which results from the first and second trimester screens are reported: as an easy
to read print out that clearly shows the risk calculations for a given trisomy of a patient’s
fetus (Figure 1).

Interpretation of NIPT results are impacted by numerous factors. For example, the positive
predictive value (PPV) of NIPT is less than 50% in low risk patients16, meaning that the
specificity is much lower than the 99% frequently cited by companies and providers alike.
This makes counseling on false positive results essential.

Multiple other factors can influence how accurate the results from NIPT are. For example,
the likelihood that a woman over 250 pounds receives a result of “no call,” is higher
compared to women under 250 pounds17. This disparity is due a dilutional effect found in
women over 250 pounds and is more common when NIPT is done earlier in the screening
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window. Finally, false-positives can occur when there is a confined placental mosaicism,
an early demise of an aneuploidy co-twin, a presence of maternal mosaicism, and if there
is presence of occult maternal malignancy17. Thus, while sensitivity and specificity remain
high for NIPT, its predictive value of aneuploidy in any given patient varies.

It is critical that physicians have concrete values for PPV and residual risk value to be able
to adequately communicate the variable predictive value of NIPT to their patient. For this
reason, ACOG and SMFM recommend that all laboratories include these values in their
result reports18. However, most laboratories do not include the PPV and residual risk value
in their reports. This is because they do not request that false positives, which are needed
to calculate PPV, be reported to them. Moreover, there is no central data collection for
reports of false positives that OBGYNs can access to estimate the PPV themselves19.
Without these values, reasonable interpretation of a NIPT result by the providing OBGYN
for any given patient is nearly impossible20.

To further complicate counseling on NIPT, there has been no established standard of
practice across the multiple specialty organizations (SMFM, ACOG, ACMG) by which
providers are recommended to determine which patients should be offered NIPT. Despite
only showing a high sensitivity and low false positive rate in high-risk pregnancies, defined
as pregnancies in women over the age of 35, NIPT is often offered to all women as the
primary screening test for aneuploidy by OBGYNs. Moreover, while administration is
most common in the second half of the first trimester, as this is the earliest time fragments
of fetal DNA can be found in maternal circulation, it is sometimes offered as a secondary
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Figure 2. A side-by-side comparison of results from a first trimester screen (left) to that of NIPT (right). While first trimester screens
provide a clear interpretation, NIPT results only communicate the level of risk of a given aneuploidy.
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screening test by OBGYNs to women who do not want diagnostic testing but are seeking
clarity on the probability of aneuploidy in their fetus after receiving an abnormal ultrasound
finding or first-trimester screen. This practice is problematic as any abnormal NIPT result
requires an additional diagnostic test to confirm the finding if there are not sufficient
sonographic findings to corroborate the NIPT results. Thus, offering NIPT as a secondary
screen serves only to delay definitive diagnostic testing. If too long, this delay could limit
a woman’s options regarding the continuation of her pregnancy.

Ultimately, without concrete risk calculations and clear guidelines on who to screen using
NIPT, obstetric providers are left unprepared to administer and interpret NIPT. A study
done in 2013 on 130 OBGYNs found 78% of them reported not being familiar with NIPT
and its associated clinical data21. Another nationwide survey done in 2014 of OBGYNs
found that almost half of those surveyed viewed NIPT as a complete substitution for
invasive testing22. More recent studies highlight the fact that OBGYN understanding of
NIPT remains inconsistent. In 2016 a survey of 103 OBGYNs nationwide found that 15%
considered NIPT to be a diagnostic test23. Another survey of maternal-fetal medicine
fellows found that although they were able to accurately answer questions related to NIPT
for trisomy 21 with high accuracy, their answers to questions regarding NIPT in twin
pregnancies and monosomy X screenings were found to be far less accurate24. This is
concerning, as it is estimated that 80% of NIPT requisitions request information regarding
the fetal sex, and disorders of sexual development account for 36% of reported discordance
between NIPT results and prenatal ultrasound or other clinical information25.
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Many obstetric providers recognize these gaps in their knowledge and cite the need for
more education as new tests continue to roll out26. At present, online training is an ideal
mode through which to provide educational material to physicians, and there are a
significant number of online resources for readers to access in order to learn about NIPT;
however, these resources range in reliability as they are subject to various levels of review.
Farrel et al attempted to evaluate the quality of a number of online educational resources
for NIPT and found that more often than not those resources had no measure of quality
review27. A significant amount of web-based information is curated by commercial
laboratories, and it is often this information that serves as an educational resource for
OBGYNs to develop and update their knowledge base about NIPT28. This utilization of
commercially developed information poses clear ethical risks for practice, as ACOG has
previously cited a concern about possible bias that can be introduced from industry playing
a role in medical education29.

Gaps in Provider Knowledge Surrounding Life with Disability
If NIPT shows a high probability of fetal aneuploidy, the expectant mother faces the
following options regarding the remainder of her pregnancy: 1) to carry the pregnancy to
term without further testing; 2) to pursue diagnostic testing before making the final decision
to carry the pregnancy to term or terminate; and 3) to terminate the pregnancy. Decisions
to terminate a pregnancy in the setting of a positive screening test for aneuploidy or
diagnosis of aneuploidy have been well documented, resulting in an overall decrease in the
number of babies born with genetic disease and chromosomal abnormalities as a result of
selective termination30-32.
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The reasons for pregnancy termination in the setting of a suspected or known genetic
abnormality are certainly complex, and grounded in a number of factors beyond the scope
of this discussion. These include, but are not limited to, the emotional and financial cost of
raising a disabled child and the effect on a family’s ability to care for their other children.
Moreover, “findings that older maternal age, greater socioeconomic status, identification
with particular races and religions, decreased strength of religious beliefs, and prior
experience with genetic testing correspond to willingness to contemplate abortion [of a
fetus with congenital anomaly]33.”

That being said, the authors wish to focus on one important factor influencing this decisionmaking process: how providers inform parents on what to expect when raising a child with
expected disability from a congenital anomaly. In 2002, a study done by Roberts et al.
found that 87% of pregnant women did not feel they got information about the future
quality of life for a child with disability. Moreover, 83% of women reported feeling like
they did not receive information about both the positive and negative aspects of raising a
child with disability34. A study done in 2005 by Skotko et al found that mothers who gave
birth to a child with Trisomy 21 diagnosed prenatally did not feel that their physicians gave
them adequate information regarding Trisomy 21 prior to initiating prenatal testing35. In
2011, a study done by Sheets et al. found that genetic counselors were more likely to
highlight negative aspects of Down Syndrome during initial discussions surrounding
prenatal diagnosis36. In 2012, a study done by Brown et al found that prenatal counseling
about congenital fetal conditions varied considerably between MFM and pediatric based
fetal care practices. Specifically, when asked their attitude about the importance of offering
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certain information when patients seek guidance on whether to continue a pregnancy in the
setting of Down Syndrome, CDH and spina bifida, MFMs were more likely to respond that
for each condition, offering options for pregnancy termination was of high importance37.
Finally, in a meta-analysis published in 2019, multiple studies showed that women did not
feel they received adequate information surrounding the experience of raising a child with
conditions such as trisomies 13 and 18 and sex-linked disorders15.

These parental reports of not receiving adequate information surrounding life with a
disability, coupled with the previously discussed barriers to informed consent for NIPT,
leads to the reasonable hypothesis that decisions made surrounding prenatal testing and
termination could be rooted in misinformation. Indeed, Press and Browner found that in a
very diverse group of women--who all underwent prenatal screening--the primary
influencing factor in their decision to undergo prenatal screening was the way in which
screening was described to them by their healthcare provider38. Moreover, the influence a
health-care provider has on a woman’s decision-making process following prenatal
diagnosis is well documented, with factors such as the provider’s approach and specialty
(i.e. obstetrician versus general practitioner) playing a critical role39. With many women
feeling that the negative aspects of raising a child with genetic anomaly are highlighted in
the prenatal counseling process, and the reported importance of offering termination to
women carrying a fetus with certain genetic anomalies, prenatal genetic testing becomes
framed by some as a
“‘search and destroy mission’ with eugenic overtones. [This, in turn]...burdens
[women] with the expectation that their individual choices not only align with their
own values, but also promote a tolerant and diverse society, one free of stigma,
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discrimination and eugenic attitudes. Paradoxically, then, the reproductive
autonomy rationale--meant to ensure that women are free to make their own
choices--forces them to shoulder the responsibility for the societal consequences of
these choices. It also frequently ignores the unequal way these choices affect
women with different socioeconomic resources in different political contexts,
especially in societies without a strong social welfare safety net13.”
Time Constraints
Health care providers need to relay a significant amount of information to their patients
surrounding prenatal screening, diagnosis and disability in order to ensure their patients are
making informed decisions. Adequate communication of this information certainly takes
time, with a simple overview of current testing options taking several minutes alone. And
yet, a recent study published in 2016 found that when health care providers offered genetic
screening to their patients, conversations about screening for aneuploidy lasted 1.5 minutes
on average, and most providers’ counseling did not adhere to ACOG recommendations40.

This finding is reflected in the literature, where women are cited as feeling that their
consultations were too short for adequate counseling about NIPT to be possible. As a
consequence, many noted that a variety of questions and concerns went unaddressed. Other
women described feeling a sense of “information overload,” and were too overwhelmed to
process the information given in the time allotted for discussions with their providers15.

While full understanding is not required for informed consent, patients should understand
the salient aspects of a proposed procedure and the consequences of proceeding with or
declining prenatal screening14. In this light, the abundance of literature showing women
who received prenatal screening did not understand what test they were receiving and why
is especially concerning.
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Routinization and the Decision Trap
As it stands, the route to informed consent for prenatal testing is both challenging and time
consuming. This, in combination with the simplicity and ease of prenatal screening tests,
raises concerns about the potential for routinization of prenatal screening. Indeed, there is
a danger that women may just view it as simply “another blood test”
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and opt-in to

testing without fully understanding the importance or implications of receiving NIPT41,43.
This is described as the “decision trap” by Silja Samerski in his book by the same name.
There, he discusses how the choice to engage with genetic technologies can become a ‘trap’
that people entered both willingly and eagerly because they didn’t understand the
implications of their initial choice. Indeed, patients start by undergoing a screening test
they considered to be routine care and are forced to face ultimate questions about the
meaning and value of human life44.

The implications of this decision trap are far reaching. Most notable are the threats
routinization of prenatal screening pose towards attitudes surrounding disability. As
Samerski puts it, “Prenatal testing creates patients who cannot be helped. They cannot be
healed, only aborted.44” This is especially true in a paradigm that does not prioritize
education of patients about disability but encourages testing and termination. Moreover, it
raises concerns about a
“possible slippery slide toward a society that...penalizes those who resist [prenatal
testing] by stigmatization and even punishing them, for instance, by ‘refusing to
allocate public funds to pay for the medical and other costs for children born with
a disorder that could have been diagnosed but whose mothers refused testing.13’”
This same paradigm could apply to women who chose to continue their pregnancy in spite
of a diagnosed disorder. Consequently,
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“while the principle of autonomy easily justifies offering prenatal testing, a narrow
focus on autonomy overlooks the tremendous pressures women face to accept the
offer of such testing and to terminate pregnancies when a serious disability or
condition is diagnosed. The burden of decision-making about whether to test and
what to do following a diagnosis falls on the shoulders of individual women.13”
The Role of the Maternal Fetal Medicine Specialist
Maternal-Fetal Medicine is a branch of obstetrics that focuses mainly on the medical and
surgical management of high-risk pregnancies. They also have special competence in the
diagnosis and treatment of women with complications of pregnancy. Moreover, MFMs
have the specific training and experience required to perform complex diagnostic and
therapeutic procedures involving the mother and or fetus during pregnancy. Finally, MFMs
provide peer and patient education concerning the most recent approaches and treatments
for obstetric problems in order to promote risk-appropriate care for complicated
pregnancies45.

Of particular importance is the role MFMs play in prenatal diagnosis of congenital
anomalies. In general, patients with positive, high risk or “no call” prenatal genetic
screening tests are often referred to MFMs for further counseling or testing. This is because
MFMs are able to perform complex procedures for advanced prenatal diagnosis, including
CVS and amniocentesis45. As such, MFMs are often the first to interact with parents of a
patient with congenital anomaly and often are the first to make the diagnosis.

Given the role of MFMs as front line in the prenatal diagnosis of congenital anomalies,
they are uniquely positioned to uphold the Reproductive Autonomy Rationale for patients
facing the possibility of undergoing prenatal genetic testing. And yet, while there is

21

abundant literature surrounding patient experience and perception of the counseling they
received regarding NIPT, little is known about the experience of MFMs as specialized
providers at the forefront of counseling on prenatal screening diagnosis and pregnancy
management.

Statement of Purpose
As such, we sought to understand how MFMs perceive the role their counsel plays in the
complex decision-making process surrounding prenatal genetic screening, prenatal genetic
testing, prenatal diagnosis and termination. We additionally sought to shed light on the
important attitudes, beliefs, perceptions about social norms and perceived behavioral
control, as described in the theory of planned behavior46,47, to fully understand the choices
MFMs make in counseling in their patients. We chose a qualitative approach as it will best
allow us to capture this complex social phenomenon from the perspective of the
participants48.

SPECIFIC AIM
To identify the key attitudes and opinions surrounding prenatal genetic testing,
disability and termination of MFM specialists who counsel expectant mothers with
a prenatal diagnosis of fetal anomaly.

METHODS
Study Design
This is a prospective qualitative study of semi-structured interviews with MFMs. IRB
approval was obtained prior to the onset of the study, and all subjects provided informed
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consent prior to participating. We enrolled participants via purposeful snowball method.
Through this method, existing study subjects recruited future study subjects from their
personal network49. This process was initiated by the MFM on our study team, AM, who
provided the medical student, AS, with referrals to MFMs in the field at different
institutions. AS reached out to each of these contacts for study enrollment. Following each
interview, AS requested interviewees to refer them to MFMs in their personal network for
study enrollment. Participant recruitment continued until conceptual saturation was
reached. We defined this point of conceptual saturation as one where we achieved both
depth and breadth in our discussions of MFM experience. This target is based on the central
tenets of grounded theory analysis, as described by Corbin and Strauss, which emphasizes
identifying and exploring a variation of concepts with sufficient detail to ensure depth of
conceptual understanding, rather than how representative our participants were of the
overall population of MFMs50.

Interviews with all study participants were conducted in English by a single interviewer,
AS. Because the literature supports the use of both face-to-face interviews and telephone
interviews within the same study without compromising the trustworthiness of findings51,
five interviews were conducted in person and 12 were conducted over the telephone. All
recruited participants were given an optional demographics survey to complete at the time
of the interview.

To facilitate open discussions with study participants, we created a semi-structured
interview guide with questions based on literature review of prior publications on the study
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topic. We then piloted the interview guide on a group of three MFM fellows for face
validity, and to determine if length and flow of questioning were appropriate prior to study
commencement. These interviews were not included in our final analysis, but allowed us
to refine our interview guide such that all questions asked to our research cohort were
clearly stated, exploratory in nature, and encouraged differences between physicians’
perceptions and experiences to emerge during the interview. The final semi-structured
interview guide can be found in Table 2. Of note, questions were added to each interview
at the discretion of AS to encourage discussion or provide for clarification of concepts
brought up by the study participant.
Tell me a little about yourself:
Tell me about your training
How would you describe what you do to someone who does not know much about
MFM?
Why did you choose this specialty (as opposed to other OBGYN specialties)?
How do you think other physicians view your job/role in patient care?
What do you see your role as in managing referral patients with prenatal/genetic
diagnosis?
When you talk to expectant mothers/parents about a prenatal genetic diagnosis, what
topics do you like to cover?
How do you organize this type of consult?
Prompt: What do you do in the case of an unclear genetic diagnosis?
Once you’ve talked about diagnosis, how do you proceed? What are the options?
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Do you give specific advice to parents about termination when you diagnose a congenital
anomaly?
Tell me more about your feelings regarding termination in this instance.
How do you handle your own biases in counseling these patients?
Is there any emotional conflict in your work with prenatal diagnosis?
Prompt: Do you have any emotional conflict …
Tell me about your hardest or most difficult patient
Tell me what’s difficult/common difficulties
What was difficult about this case?
What did you struggle with the most?
Could you imagine raising a child with a disability?
Prompt: What if it is a severe disability?
What if the child requires long term intensive care?
What do you imagine life is like for kids with a disability as a result of a genetic disorder?
How does that impact the advice you give to parents about raising a child with
disabilities?
Tell me about your patient population
Are there any characteristics about your patient that might change your approach or
interaction?
Is there anything else you feel impacts your approach? (Prompt: culture/religion/financial
status)
Prompt: How does that affect the way you feel about what a patient should do?
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Tell me about the reactions, interaction and conversations with parents after
providing the option of termination
What is the most surprising thing you heard a patient say in response or after their
consult with you?
What do you think a patient leaves the room understanding after your discussion
about termination?
Who do you think influences a patient’s decision?
How do you incorporate family into your discussion?
Outside resources
What support services do your patients have access to?
Do you refer your patients to other providers (genetic counselors, social workers,
care coordinators) to help them understand their child’s condition better?
Do you have a pediatric or neonatal palliative care specialist?
Do you refer your patients to pediatric specialists to prepare them for
complications they might face once their child is born?
Do you personally perform terminations, or do you refer patients if they desire
abortion?
Does your institution have a family planning division?
Table 2. Questions from our interview guide. The questions above were used to jumpstart
conversations with MFMs.
Data Analysis
Each interview was digitally recorded and transcribed verbatim. Transcripts were then
imported to NVivo (Version 12.6, QSR International, Burlington, Massachusetts, USA), a
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qualitative software program that helps to organize and retrieve data for qualitative
analysis. Analysis of this data was conducted by a medical student (AS), a MFM (AM) and
a neonatologist (MD). As described above, transcript analysis was conducted using a
grounded theory approach, wherein the researchers conducting this study independently
analyzed a subset of transcripts, and attached descriptive codes to segments of text in each
transcript. Following this independent first-pass analysis, researchers met to discuss their
impressions and reconcile variations in their developing codes. Once discrepancies in
codes were reconciled, codes were grouped into broad topic-oriented clusters. Within each
cluster, codes were assigned to a specific “theme.” These themes allowed us to construct a
cohesive idea or theory about an investigated phenomenon, and served as the basis for our
coding framework, which was then used to code subsequent interviews. As our
understanding of these themes deepened, we further classified codes according to “subtheme.” Simultaneous data collection and analysis allowed for an iterative process wherein
investigators would independently analyze interview transcripts, identify and agree upon
emerging themes to subsequently pursue in the following interviews50. Analysis concluded
when theoretical saturation was reached, as described above.

RESULTS
In total, we interviewed 17 participants. Of these, 15 returned a completed demographics
survey, and their responses are shown in Table 3. Of the MFM’s who returned a
demographics survey, nine were female and six were male. The majority of respondents
were under the age of 45 ( n = 9). Additionally, the majority of respondents (n =11) reported
practicing at a major academic center. Finally, while the greatest number of respondents
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were from the Northeastern United States, we were able to interview MFMs practicing in
all major regions within the continental United States: North East, South, Midwest, and
West.

Coding analysis of the interview transcripts yielded a total of 2,227 codes grouped into six
clusters. Codes were then characterized to triangulate MFM perspectives into 18 themes
and 39 sub-themes, shown in Table 4. These findings express the varying perspectives on
the MFM providers’ role in counseling expectant parents on prenatal genetic testing,
disability and termination.

Interview Clusters and Themes
1. Physician Methodology
Our first cluster, Physician Methodology, includes statements made by MFMs describing
the approach they take when counseling patients on all issues related to prenatal screening,
testing and diagnosis. We identified four major themes to characterize the overall structure
MFMs follow when counseling their patients.
Physician Goals
First, MFMs described their approach to prenatal counseling as being rooted in goals
identified prior to each counseling session. While some MFMs described universal goals
to ground each discussion with patients, others felt it was important to tailor each session
to the patient’s goals.
[I] try to identify their goals for the visit or for the testing. What their background
or fund of knowledge is, and how we can meet their goals. (MFM 17)

28

Universal goals were rooted in the notion that all patients are entitled to as much
information as possible:
I think it just comes back to my whole philosophy of practice [which] is that it’s not
my choice to make anything. It’s my place to inform them, and help them to
understand and make them aware of their options and whatever their options-whatever they choose--help them access that option. (MFM 15)
Establishing Diagnosis
Second, an MFM’s approach to establishing a prenatal diagnosis varied based on the level
of information surrounding the diagnosis that their patient came to the MFM with. In
general, MFMs saw themselves as on the frontline for both establishing the diagnosis and
explaining the implications of said diagnosis to the patient.
I feel like pretty much the first line of communication with the patient and family
who have some new issue or complication in their pregnancy and really going over
with them what that means, what their options are and what the next steps are.
(MFM 14)
This sentiment was felt to be especially true with referral patients.
You have to keep in mind I am not usually the first person that someone sees
because of my job description, so they usually know that there is something wrong
and that I am there to explain to them what is wrong, basically. Because they
understand [that] there is some sort of a complication and that they need a
specialist and that’s why I am there. (MFM 10)
Whether or not the MFM was the first to walk the patient through their prenatal testing
options to reach a diagnosis or if a patient was referred to the MFM with concerning
findings in hand, MFMs described their approach to establishing a diagnosis as
multifaceted. Steps to take included gathering appropriate imaging, establishing a wide
differential diagnosis, reviewing potential genetic associations to the identified anomaly,
and counseling patients on how their pregnancy management might be impacted based on
the findings and potential diagnosis.

29

Best Practice
Interestingly, while discussing their overall approach to patient counseling, MFMs
repeatedly referenced parts of their methodology they considered to be paramount to
appropriate counseling, what we called ‘best practice.’ This included how MFMs tailored
their consultation to meet the goals they defined for the consultation. Although almost all
MFMs referenced how they thought it was most appropriate to deliver bad news to patients,
we noted two separate approaches. While some MFMs felt it was necessary to cushion or
qualify the delivery of bad news to make it easier for patients to digest, others felt they had
an obligation to patients to be as up-front and direct about the bad news as possible.
I try not to finalize anything immediately...They say I’m having them come back
because I think, you know, that I’m wrong or I’m trying to soften the blow [but] I
said...I just don’t like to make these diagnoses that are going to affect decisions of
Life off one ultrasound, so I’ll give the baby one more week and take a look at it
again. (MFM 1)
When I was a fellow I actually helped with a support group for women who
terminate wanted pregnancies because of a genetic or ultrasound diagnosis...they
[also] said they often could tell there was a problem before someone actually said
there was a problem, and they don’t like that. So that’s the first thing I do when I
walk in the room. I say: ‘Hi, I’m Dr. MFM 4, nice to meet you, I’ve looked at your
images and I want to let you know I think there’s a problem’ because I think the
prolongation of even just saying those words builds more anxiety in the patient.
(MFM 4)
Repeatedly, when discussing what they thought to be best practice when counseling
patients, MFMs emphasized the value of consistency in counseling. This was generally in
reference to whether or not MFMs tailored their approach based on certain demographic
characteristics of their patient.
Their responses vary, I’m sure of that. My approach doesn’t. (MFM 3)
I’m going to discuss pretty much everything the same with the patient regardless of
her, you know, insurance status, socio-demographics, or anything...regardless of
their religion, I’m still going to say the same thing. (MFM 5)
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Tasked with having to communicate complex and difficult information during a single
counseling session was noted by many MFMs to be extremely difficult. This is both
because the MFMs felt patients often find information difficult to digest in one sitting, and
because MFMs felt that when tasked with making decisions about termination, patients
should be given time to process before they make such a permanent decision. To that end,
MFMs describe repetition as a valuable tool in order to help patients understand what a
diagnosis means for them and the future of their pregnancy.
You know, sometimes I think people are not ready to understand everything and it
may take more than one visit for the information to sink in…[so] we will go through
it again and sometimes another time. (MFM 12)
All MFMs interviewed felt they had a professional obligation to discuss termination as an
option in the event that a patient was given a prenatal diagnosis of genetic anomaly. Many
noted that discussions surrounding the option of termination are extremely loaded, and
have the potential to become points of contention during a counseling session. MFMs
described ways they diffused this tension through neutral language to normalize the
conversation.
I’ve sort of learned to always couch it as “hey look, we’re going to talk about
something that’s really uncomfortable for people, but me as your doctor you know,
I think it’s really important for me to at least bring up. I’m not your friend, I’m not
your family member, I’m not your priest, I’m not your pastor, like here’s the doctor,
we’re going to talk about this. And if you never want to hear this word again, if you
never want to speak about it again, please let me know. But I always sort of say it’s
my obligation as your healthcare person to at least bring it up. (MFM 6)
One MFM discussed framing the topic using neutral, nondirective language.
I think our job as MFMs is not meant to be prescriptive. I think especially in a
situation like this where there are things way above and beyond what we do that
are involved in this decision….we have to try and not insert our personal beliefs
onto this situation and let them make this decision themselves...unless I see an
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obvious reason to [guide patients in one direction or another] I try to be as neutral
as possible...we respect your decision one way or another we will support you with
either decision...but we just want to make sure that you know you have the
information to make the decision that is right for your family. (MFM 13)
Beyond the use of neutral language, many MFMs felt it was easier to approach the option
of termination by framing it as an option many patients with the same diagnosis have either
considered or taken. By saying termination is something other people with the same
diagnosis have pursued, many MFMs felt they were making the option both easier to digest
for the patient, and easier to accept for patients leaning in that direction.
So the phrase I usually use is like, ‘There are some people who, when seeing this
on ultrasound, would choose to end a pregnancy or would choose to terminate a
pregnancy or would choose to not continue’ and see, depending on who I’m
speaking to, one of those phrases, so that they hear that this is an option for them
that’s...I don’t want to say reasonable, but that people do this. And in my mind
somehow using that phrase allows them to accept that a little bit more. (MFM 7)
Finally, to achieve best practice MFM providers described the importance of consulting
colleagues especially when they felt they were not the best person to answer specific patient
questions. In those instances, many relied on the expertise of their colleagues either in the
field of maternal fetal medicine, genetic counseling or pediatrics in order to help patients
get all the information they needed to make a decision about their pregnancy.
So, for example, if...a woman’s fetus is diagnosed with Down Syndrome...I can talk
to her about it generically, but I don’t take care of children with Down Syndrome.
So, it would be difficult for me to tell her, ‘Oh this is what it means--your child will
need this and your child will need that and this is what to expect,’ because it’s not
my specialty. So, I can speak in very broad strokes, but ultimately…[I would try] to
help her get information either, I mean usually from professionals, whether they’re
pediatricians who take care of children with Down Syndrome or geneticists or even
the internet or what not. But generally a consultation with someone who takes care
of these kids to give the woman a better sense of what this means. (MFM 16)

Gender
Female

9

Male

6

Age Group
24-34

1

35-44
45-54
55-64
Practice Location
Midwest
Northeast
South
West

Years in Practice
0-4

5

Religion
Agnostic
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2

5-10

1

Atheist

3

11-15

3

Catholic

3

16-20

3

Jewish

2

26-30

1

Orthodox Church

1

31-35

1

Prefer not to answer

1

Protestant

3

8
4
2
Political Identification
Conservative

1

4

Type of Practice
Academic

Independent

3

11

Liberal

6

Hospital based clinic 1

Prefer not to answer

2

Employee of HMO

1

Progressive

3

Private practice

2

6
4
1

Table 3. MFM Demographics. Participating MFMs had varying levels of practice and came from diverse backgrounds. We spoke with MFMs from
all over the U.S., including those from the Midwest (ND, SD, NE, KS, MN, IA, MO, IL, WI, IN, MI, OH), Northeast (ME, NH, VT, MA, RI, CT,
NJ, NY, PA), South (TX, OK, LA, AR, MS, AL, GA, FL, TN, SC, NC, KY, VA, WV, DC, MD, DE) and West (WA, OR, CA, AK, NV, AZ, NM,
HI, CO, UT, WY, ID, MT, WY).
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Clusters

Themes

Physician

Physician Goals

Sub-Themes

Example
“It’s just making sure that they have as informed consent…as they possibly

Methodology

[can] have and whatever I can do to give them that I think is my goal.”
Establishing

“What I like to do is…to try to get as much information as possible prior to

Diagnosis

the patient coming, from her referring doctor, what their concerns were
based on the ultrasound…And then sit down with the patient, her family,
and anybody else, to really have the opportunity to discuss everything in the
context of our findings… and explain what we see and how it impacts on
that diagnosis.”

Best Practice

Delivery of Bad

“I would say [I am] very direct in counseling. I try not to sugar coat anything

News

because it doesn’t help anybody I feel like while they might be angry with
me in the beginning about it, they have time...they would be angry regardless
of who delivered that news. It’s not me, it’s the news.”
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Consistency

“Understanding what their cultural and religious beliefs can sometimes be
helpful in counseling them…but I still provide them all with the exact same
counseling.”

Repetitive

“It may take more than one visit for the information to sink in….and we’ll

Counseling

sit down and we will go through it again and sometimes another time.”

Neutral Language/

“I feel like it’s particularly important to discuss it [termination] in an

Normalizing

unbiased way for prenatal diagnosis patients.”

Termination
Colleague Opinion

“…sometimes it’s better to ask for a second opinion from a colleague or
somebody who’s kind of looking with fresh eyes at the case and who the
patient hasn’t already associated with receiving bad news and a negative
experience.”

Barriers to Best

Inconsistencies in

“I don’t like when people order the test and then the patient really didn’t

Practice

Practice

want the test. I think that makes it challenging that we have some providers
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who will do certain tests and then the patient doesn’t want to know the
information…”
Technical
Limitations
Time

“A patient is scheduled for a number of minutes, so if there’s an abnormality,

Restraints

clearly you need to spend more time…but in the back of your mind there’s
always just like the [thought that] others are waiting for you to see [them] as
well.”

Scientific

“But like, with down syndrome we can’t predict how severe the disability is

Limitations

going to be. So, we’re very careful not to, you know, promote one way or
another. That if you’ve got this diagnosis of down syndrome that you’ll have
mild intellectual verses severe intellectual disability, I guess, it’s often the
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moderate to severe. We always tell them that genetics, in amniocentesis
results, can’t predict that.”

Unclear

“Well then we have to tell them we don’t know...this is I call it the dark

Significance

side of prenatal diagnosis. Stuff that is uncertain, and depending on the
location and the size is why we have genetic counselors, and they help us
to counsel if there’s any potential bad implication but the reason it’s
unknown is that it’s so rare, problems with is are so rare…”

Lack of

“I have really zero concept of what it might be like to live with a child that

Understanding

has disability.”

about Disability
Physician

Objective

Define Disability

“I think it depends on the disorder. Some kids live their life in bliss, some

Perception of Viewpoint

kids live their life without any recognition of it because they don’t have the

Disability

capacity to recognize it. And for some kids, it’s very difficult based on their
cognition of it and their experience compared to other kids. So I think it
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ranges, sort of between a bad and difficult life to a very happy life and
everything in between…”
Define Severity

“[I define a severe anomaly as one that] would need for a pediatrician to
attend to the patient at the time of delivery or soon after….something that
requires intensive care.”

Define Lethality

“…lethal is a moving target. Like twenty years ago…lethal was completely
different than lethal is today. And there was that editorial in JAMA
pediatrics…about Rick Santorum and his daughter and just the shifting place
of the word lethal.”

Subjective
Viewpoint

Chasing Perfection

“I think that there’s this search for perfection in the world. And I understand
it, I’m a parent, like I get it, I get it very very strongly. But I think that wewe’ve come to expect things in life that aren’t possible, this idea of a perfect
life.”
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Common

“Don’t forget, 3% of all pregnancies have significant congenital abnormality

Uncommonality

however it’s….quite a bit of patients are normal and everything…but when
you start getting specialized, pretty much everybody has something.”

Stigma of

“Whatever you’re given [if your child has any disability] …there’s a

Disability

community for you…So, it just felt ‘normal’ as a term is so heavy and so
judgmental. That I just can’t say it anymore, it just doesn’t come out
anymore.”

Physician’s

Defining Moral

Experience

Role

Moral Distress

“Yeah, I think that I have a difficult time personally, um, with aborting a
pregnancy that isn’t again, a lethal condition or a situation where the
mother’s health is at significant risk.”

No Judgment

“It’s not for me to tell the family whether that’s a pregnancy “worth
terminating.” So, if someone says to me, I’m going to have a termination, I
say ok, I help them with that. And if they say we’re going to keep the baby,
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I say great, you should probably meet with someone who takes care of these
kids so you have a sense of what to do. And I uh, go that way.”
Not My Role

“It’s not my place to tell her what to do, it’s just not in the conversation at
all.”

Pro-Choice

“I support it. I mean, I do them. Um I have always been very pro-choice, I
donate to planned parenthood, I used to work at planned parenthood as a
resident.”

Pro-Genetic Testing “So you know while I think the old school thinking is only get these [genetic]
tests if you’re thinking you might consider termination, I would say that’s
silly, I mean if knowledge is power right?”
Emotional

Difficulty

“…people get very sad. And um, especially for things that are ambiguous –

Response

Conveying Bad

I’m thinking like posterior fossa abnormalities, like Dandy-Walkers, I don’t

News

freaking know what to tell people. I find those very, very, very hard.”
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Empathy

“It’s easy to sit from here, to make comments to the patient’s choices and
everything but unless you are in their shoes, unless you are facing that
question at a personal level, it is not a question that can be answered.”

Fear of Being

“I think we’re very careful so that it doesn’t sound like we’re recommending

Perceived as

or suggesting abortion. So, I don’t think that people get mad at us for that.

Coercive

But I have seen instances where people get mad. ‘Why would you ever tell
me to kill my baby?’ Um, and uh, but I don’t, that doesn’t typically happen
to me, fortunately.”

Self-Doubt

“[…] in situations where I feel like I must not have explained or counseled
well enough for the patient to have a truly good and logical understanding
of the situation…And so then I feel that I myself am to blame for not
providing enough education and counseling for them to have a true
understanding.”
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Physician-

Effective

Patient

Communication

Avoid Jargon

“So there are a lot of people I’m explaining what a chromosome is—they
don’t understand that you get a set from your mom a set from your dad. So

Relationship

I use colloquialisms or other terms like for example for like the karyotype
or the chromosomes I use the word ‘blueprint’ or ‘these are the instructions
that tell the cell to do what it needs to do.’”
Eliciting Patient

“I start with asking the patient what they have heard already and what their

Understanding

understanding is of the diagnosis is and try to tailor my counseling based on
that kind of what their level of understanding already is.”

Responding to

Handling Family

“In some instances, we notice that the [family] dynamic might not be a

Parental Needs

Dynamics

healthy dynamic so we cannot let that go so we try sometimes [to make]
excuses…we try to catch the patient while she is not with the other person.”

Patient Dictating

“It depends on the woman of course, what her—what she considers as an

Care

option or not an option for her.”
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Reactive Values

“I really just say from the get-go that I am required and obligated to offer

Elicitation

you all the full range of options, but some families tell me that they would
never consider pregnancy termination, and if that’s how you feel then I
won’t talk about it anymore.”

Shared Decision Guiding Family

“And that’s what I think the role of the doctor is, not to tell them what to do

Making

but to put things into context for their decision.”
Informational Role

“I try to give some examples, I give them a little bit of time to digest, ask
questions, and often I ask them to tell me what they are understanding so
that I feel whether they were able to receive the diagnosis I try to deliver to
them.”

Maternal versus

“If it’s something lethal…I might talk more about termination and also

Fetal Health

related to risks of continuing pregnancy for mom. Because just being
pregnant is a higher risk condition than not being pregnant.”
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Patient

Cultural

Experience

Influence

Faith

“I often try to get a sense, even near the beginning of counseling, of whether
or not the family has given any thought to pregnancy termination. And most
families are pretty open with me in terms of if they feel like based on their
religious view or personal values that it’s something they would never
consider…”

Familial

“I think family’s like the number one influence…most patients really rely

Influence

on their families and their spouse.”

Barriers to Care

Socioeconomic

“I’m upfront with them with the options, telling them that this one here could

Barriers

be very expensive, you know we can see what we can do to help decrease
the price but I also think you can’t go through the counseling and tell them
all the options and then they choose the one that’s going to cost them
$20,000…”
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System Barriers

“We’re limited by practice in a federal hospital where, by law, we’re not
allowed to perform a termination unless it’s rape, incest, or life of the mother
[is at risk]…”

Emotions

Patient Hope

“I quickly realized that she was a reasonable person in an unreasonable
situation, and this was a pregnancy that was so desired after years of IVF
and want not…she was sort of grasping for anything.”

Patient Regret

“…there are parents who say now that my child is 14, 15, wheelchair bound,
you know all these things I would not have chosen what I did.”

Inability to
Understand
Child’s
Condition

Language Barriers

“So with a language barrier all these difficulties and these grey areas become
so much more complicated to communicate…”
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Termination Abortion
Culture

“In general, the population is a fairly politically conservative and there’s a
pretty low rate of pregnancy termination even after a prenatal diagnosis or
genetic abnormality.”

Abortion

“I think it’s going to be interesting to see what happens in the next year or

Tourism

so because I think we could start having a lot of abortion tourism here. So
that could be very interesting to see from our perspective. Because we will
be doing ultrasounds and there might be a lot more anomalies and stuff
coming now to access our abortion services.”

Legal

“It is a very strange law [where] you can’t terminate in Pennsylvania or

Considerations

Ohio anymore based on Down Syndrome, so…basically, a patient can
terminate at 20 weeks if she doesn't want the pregnancy, but [not] if the
baby has Down syndrome.”

Table 4. Thematic clusters from interview analysis. We subdivided clusters into themes and sub-themes for more nuanced and detailed analysis.
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Barriers to Best Practice
In addition to emphasizing how to best approach a patient undergoing prenatal counseling,
MFMs discussed barriers they faced in attempting to meet the benchmarks outlined in the
“Best Practice” theme. Of these, we identified three principle sub-themes: Inconsistencies
in Practice, Technical Limitations and Lack of Understanding about Disability.

MFMs expressed frustration surrounding inconsistencies in practice between themselves
and their colleagues both in maternal fetal medicine and in pediatrics. MFMs felt that in
these instances, counseling of patients was compromised as they received different
messages from different providers.
What does not work is when one of your partners has seen the patient and has
already promised them the world. You know, we'll do a C-section, we’ll do anything
you want. And then I'm seeing them or I'm on labor and delivery when they come
in and I have to deal with all of these things that I think are wrong, but you know
my partners have already planted the seed because let's face it if there's x# of us,
there’s a 1 out of x# chance you're going to be the one delivering the baby, so it's
probably not going to be you, so you can tell them anything you want to get them
out of the office. (MFM 1)
Unfortunately, because our NICU is so pro-life it puts the MFM's in a very hard
spot because how can [they] plan to do a resuscitation on a kid and us not do
anything from an antenatal standpoint to prepare that child for life because we
know earlier that baby [would need] magnesium and steroids...how do you [as an
MFM] withhold that stuff if [the NICU] going to intubate the kid…[our
relationship with the NICU is] a little bit dysfunctional. (MFM 2)
MFMs also expressed frustrations surrounding the inconsistences or lack of prenatal
counseling their patients received prior to consultation. Multiple MFMs highlighted
instances in which their patients had received poor prenatal counseling by their referral
providers.

47

It’s almost like what happens is now that we have cfDNA [it’s] even worse because
patients aren’t counseled appropriately. They’re just getting it, low risk patients
[...] they’re not being counseled appropriately before being sent to us. (MFM 1).
I find that that’s a very confusing topic for lay people, for parents, for med students,
for residents. I think that the average patient, um pregnant woman going into the
doctor’s office, is not counseled appropriately in any way shape or form because I
don’t think general OBGYN’s have the time or frankly the knowledge to go through
all that, and they all have their own biases as well. (MFM 8)
Ultimately, MFMs felt that inadequate counseling by referral providers saddled them with
the task of having to deliver bad news to unsuspecting patients.
The OB really, I don’t think had not prepped the family for how bad it was. So
maybe they walked into our office thinking maybe the head was a little big. And I
think I walloped them with just something horrible. (MFM 6)
MFMs also felt that various technical barriers served as barriers to their best practice. The
first of these barriers were time constraints. These constraints were noted to exist both
within the context of the appointment itself, and in the broader sense when considering
how long a woman has to make a decision regarding her pregnancy. Because the majority
of states in the United States do not offer late term abortion, women are forced to make
decisions regarding termination sometimes only a few days after receiving a diagnosis of
anomaly in their fetus.
Just time...you know there’s...other logistic problems as well. You know a patient
is scheduled for a number of minutes, so if there’s an abnormality, clearly you need
to spend more time. [But] in the back of your mind there’s always...others waiting
for you to see as well [...] [Ultimately] it is an arbitrary decision, isn’t it? Just like
how much time you think you should spend with patients or you can afford to spend
with patients. (MFM 15)
There are sometimes emergency situations where you have a quick decision [to
terminate]...[sometimes] a few days if not a few weeks to make a decision to
terminate. (MFM 12)
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Complicating matters is the second technical limitation identified by MFMs: scientific
limitations. Indeed, inherent to prenatal diagnosis is a level of uncertainty regarding the
outcome of a diagnosis as we are rarely able to predict the exact manifestations of an
aneuploidy. As one MFM described:
The diagnosis is always assumptions. It’s never 100% certain, so trying to explain
how to make sense of this uncertainty and trying to pinpoint….I cannot provide that
answer to them. It makes them even more frustrated, so that’s I think, the biggest
thing about my job. (MFM 15)
Certainly, anomaly exists on a spectrum that we have some insight to but cannot predict.
MFMs also touched on how the limitations in the science and technology available for
prenatal diagnosis make prenatal counseling challenging.
I think a lot of what we do….raises anxiety for no reason. I think a lot of it is
basically us trying to prove how smart we are when the reality is we don’t know
anything until the baby comes out. Most of the time [it leads to] weeks of anxiety.
(MFM 1)
Indeed, in many instances of prenatal screening and testing, patients receive information
they were not expecting. In response, MFMs described a sense that the current diagnostic
technology we have has outpaced our knowledge on the implications of certain genetic
findings. This was felt to be especially true in reference to the use of microarrays for
analysis of genetic material, as this method often turns up “Variants of Unknown
Significance,” or genetic anomalies that may or may not be pathogenic. This sense of
unclear significance, our final technical limitation, was referred to by one MFM as “the
dark side or prenatal diagnosis” (MFM 3), as it leads to the communication of a “diagnosis”
without actual evidence to show whether the diagnosis was pathologic or simply a benign
variant.
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The final barrier to best practice highlighted by our MFMs was the fact that many did not
actually feel qualified or prepared to speak on life with a disability. For some, this lack of
understanding stemmed from a lack of familiarity with existing literature, or minimal
interactions with disabled persons. For others, they felt they could not understand and
therefore could not counsel on life with a disability because they did not experience
disability themselves. Either way, this lack of understanding surrounding life with
disability served as a major limitation for MFMs when trying to counsel their patients on
the meaning of a diagnosis of a congenital anomaly resulting in a disability.

2. Physician Perception of Disability
The concept of disability and how it was perceived by our interviewees emerged as our
second major thematic cluster. This cluster emerged from statements that captured the
personal definitions MFMs used to describe disability and their varying perspectives on
topics surrounding disability. We grouped these statements into two main themes, objective
viewpoints and subjective viewpoints, and seven total sub-themes.
Objective Viewpoints
The need to describe to patients what disabilities could be associated with prenatal findings
that arose during consultations was a common finding in interviews. From this discussion
emerged the concept of needing to set objective parameters for dialogue. Providers shared
their perceptions of what disability meant. Consistent among MFM definitions of disability
was the use of the term “spectrum” to describe disability. The way MFMs defined each
end of this spectrum were based on a number of factors. Some used the terms ‘major’ and
‘minor’
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Trisomy 13--major. Multiple, multiple, severe anomalies, like a big abdominal wall
defect with abnormal limbs and a big-you know-an enlarged brain and you know a
big heart defect, that's not good. Something in between would be a major heart
defect. Something minor would be clubfoot or ventriculomegaly. You know in my
mind everybody has their own scale. (MFM 4)
Others defined their spectrum of disability based on their perception of a disabled
individual’s quality of life.
I think it depends on the disorder. You know, I mean I think nowadays, for many of
these, many infants that are born with Down Syndrome who get an early
intervention program and all that, I think for many of them for those children, they
can have a meaningful existence, very pleasant, happy lives. And some of them can
be very functional, or pretty functional, depending on what their genetic
background gives them in terms of parental intelligence. But, you know, for many
of them, they will have significant lifelong challenges. I think for some of the other
more significant genetic disorders, I think their life is much much more challenging.
(MFM 5)
I think quality of life is something that we’re all very poor at measuring and we all
have different markers for what defines someone’s quality of life. And I think some
of that is personal, so I think it’s more describing to the family what this child’s life
is like. You know, I’ve had families who are happy because their child is able to
smile. Other families, they’re happy because their child is able to eat. And you
know, other families who would be very disturbed by those things if they weren’t
able to feed themselves, if they weren’t able to go to a regular school. (MFM 9)
Multiple MFMs defined this spectrum based on their perception of a disabled individual’s
level of awareness surrounding their disability. Meaning, there exist disabled individuals
who are unaware of their disability or difference, and are able to live happier lives than
those disabled individuals made to be aware of their disability. Some MFMs referenced the
ability of disabled individuals to experience happiness as a qualifying factor of their
spectrum of disability. Others defined disability as a nonmainstream condition. Finally, the
degree of visibility (i.e. intellectual versus physical versus both), and the degree of
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additional care a disabled individual would require were evoked by providers to describe
the spectrum of disability.

The concept of a “severe disability” came up multiple times throughout our interviews.
Usually, the degree of disability severity served as the basis for the MFM to discuss
termination options with their patient. As such, we asked MFMs to describe their personal
definitions of disability severity in order to get a better understanding of what they would
consider reasonable grounds for termination assuming the condition could be diagnosed
prenatally. MFMs also identified conditions they did not consider to be severe and thus did
not or would not warrant termination.
People with obviously lethal or severe abnormalities, lethal in the neonatal period
or the early childhood period, yeah, I certainly have that discussion with them
[regarding termination]. [...]For people with minor abnormalities, I don’t typically
have the discussion with them, especially if they have declined genetic testing about
pregnancy termination. (MFM 5)
I don’t bring it [termination] up with cleft lip palate, for instance. Um, I don’t
bring it up with something like gastroschisis, which is something very surgically
resect-able. All of this is nuance. With anomalies that are fixable and don’t really
impact the quality of life, I normally don’t bring it up. (MFM 6)
The severe one. Uh, something like Fragile X or cerebral palsy that was severe or
probably Downs Syndrome probably in that more severe category. (MFM 14)
We also found variability in what MFMs conceived as lethal conditions. Some MFMs were
hesitant to use the term lethal to describe a condition if a fetus could survive with their
condition for a few minutes following birth. Other MFMs were hesitant to describe a
condition as lethal due to developments in medicine that allow for more conditions to be
survivable.
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They don’t call it “incompatible with life” we call it “life-limiting” here in Ohio
because we're not allowed to say the other one [...]Yeah so when I say “lifelimiting” I mean like “incompatible with life.” It's been ingrained in me here, they
don't like the other one [...] here they will do a C-section on a t13 so that if the mom
wants to spend some time with the baby before it dies. [...] Yeah and we're not
unique to it you know there's all kinds when you discuss viability what it is its
definition it is very murky and cross in. (MFM 2)
I don’t even want to use the word lethal, because lethal is a moving target. Like
twenty years ago, and I keep telling this to our fellows too, twenty years ago lethal
was completely different than lethal is today. And there was that editorial in JAMA
pediatrics, did you read that one, about Rick Santorum and his daughter and just
the shifting place of the word lethal. (MFM 7)
But we always bring termination up as an option whenever there is a severe birth
defect that will affect the fetus after birth. Um, particularly if it’s lethal or if it’s life
limiting, is another term that we’ll use. People don’t really like the term “lethal”
as much anymore. Or if it’s something where the fetus has a high mortality, the
neonate I should say, or the fetus, because a lot of the diagnoses will have a high
fetal demise rate as well. (MFM 8)
Subjective Viewpoint
In contrast to providers’ attempts at objectively describing disability, we identified
statements discussing the subjective viewpoints MFMs had surrounding disability.
Throughout our discussions on disability, many MFMs referenced the notion of
‘perfection’ that they feel patients have come to expect in their pregnancies perhaps as a
consequence of the connotation a “positive screen” or “positive diagnosis” confers onto a
fetus. MFMs referenced this sentiment among patients who view their fetuses as less
desirable or less perfect because they carry a particular diagnosis even if, chances are, the
fetus would not have been perfect diagnosis or not. As one MFM put it:
I think first people initially have to grieve that their perfect child isn’t perfect. We
all have imagined perfection in our children, and it’s never true [laughs]. (MFM
3)
We found that while congenital anomalies and their associated disability are considered to
be rare in the general population, MFMs noted that for them they are relatively common in
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light of their overall practice population. This is because of the specialized nature of the
MFM’s practice.

To varying degrees, MFMs referenced what we perceived as general stigma surrounding
the concept of disability and what it means to be disabled. One MFM referenced this stigma
in the context of patient reactions to diagnosis of an anomaly. In reference to the
community she served:
It is well known in [this] community that if [you] have a child with Down Syndrome
they actually get shipped off to like –I don’t even know what its called- it’s like
facilities where these children are just take care of because it’s seen as such a bad
mark on the family if you have a child with disability. Because like so much of the
importance of the female in their culture is for propagation. You know? So if you
are seen as having any blight on your record that's a really big deal. And you can
be shunned from your community or your husband could turn you out basically.
(MFM 4)
Another discussed this stigma in the context of how pregnancies that do not carry a prenatal
diagnosis are considered to be ‘normal,’ while those that do are not.
I don’t know that I made that uh that very like a cog – “today I’m going to start
saying typical.” But I have changed the way I approach things. [...] It just felt
normal as a term is so heavy and so judgmental. That I just can’t say it anymore, it
just doesn’t come out anymore. (MFM 7)
3. Physicians Experience
MFMs detailed their experiences counseling patients as being incredibly emotionally
involved. We grouped MFM statements in this cluster into two overarching themes and
nine sub-themes that fit under the cluster of physician’s experience.
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Defining Moral Role
MFMs frequently brought up their moral role in consultations. In general, we use the term
role morality, or the theme, “defining moral role,” to describe statements made by MFMs
where they indicate that they see themselves as playing a certain supportive role with the
burden of ethical decision making falling on the patient. Thus, MFMs are able to subvert
their own ethical reasoning so long as the patient’s ultimate decision is ethically
permissible. In their capacity as an MFM, providers viewed themselves as needing to be
non-judgmental and unbiased. Consequently, MFMs described themselves as supporting
their patients in whatever decision they ultimately made, even if they personally did not
agree with it.

When a patient’s choice regarding termination of a pregnancy was not in line with the
choice the MFM would have made, many expressed a sense of moral distress. In particular,
MFMs mentioned instances where patients terminated their pregnancy for conditions the
MFM considered to be not worthy of termination. These included Down Syndrome, cleft
lip, ambiguous genitalia, heart defects and clubbed foot.

Despite their own moral distress, MFMs repeatedly discussed their efforts to not judge
patients based on the decisions they made regarding their pregnancies following a prenatal
diagnosis of anomaly. This was especially true in the instances where they did not feel they
would make the same decision as the patient.
I can’t provide the option [of termination] but I can provide the avenue and try not
to be judgmental about whether they would consider it or not for whatever
indication, if it arises...I would try to be supportive of whichever decision they
make. I try not to say [that] I probably would not perform a termination if my child
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had Down Syndrome, but I have had lots of women that do. So I realize that’s my
more conservative [opinion]...But I try not to be judgmental or I recognize that’s
my own belief and it isn’t something that’s universally held. (MFM 17)
MFMs also felt that they could not judge a patient’s decision because they are not the ones
who have to live with the consequences.

Underlying this sense of duty to not be judgmental was the sense that determining what
they would do if the situation was reversed was not their role. For instance, a frequent
occurrence referenced by the MFMs we interviewed was a patient asking them, during
some point in the counseling process, what they (the MFM) would do when faced with a
prenatal diagnosis of anomaly. This question usually arose in the context of a patient
considering termination. In response, MFMs felt that it was never their place to answer this
question.

Our final two sub-themes were pro-choice and pro-genetic testing. We used the theme
“Pro-choice” to group statements made by MFMs that expressed pro-choice sentiment.
This was generally in relation to a patient’s choice to terminate a pregnancy, but MFM’s
discussed being Pro-choice in the context of management decisions with regards to the
patient’s pregnancy. Some MFMs expressed strong sentiments towards the value of genetic
testing. Specifically, they felt that genetic testing was on balance a positive choice, as it
equips patients with valuable information to better manage their pregnancy. As one MFM
put it, “knowledge is power, right?” (MFM 4)
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Physician’s Emotional Response
All MFMs detailed the emotions they experienced while counseling patients. More often
than not, MFMs are put in the position of conveying bad news to a patient. The difficulties
they describe in the process relate to their own emotional response when delivering this
news. While MFMs emphasized a professional obligation to deliver and explain bad news
to their patient, they noted their own emotional response as they coped with the difficulties
of such a task.

Despite the emotional difficulties MFMs experienced when conveying bad news to their
patients, many expressed a sense of empathy for their patients receiving bad news. While
many could not relate to the choices the patients were facing, they did describe a sense of
sharing patients’ emotional response. Some MFMs described learning from their patients’
reactions to bad news, while others discussed connecting with patients on a personal level.
That was really very educational for me as far as uh motherhood doesn’t have to
be a lifelong experience. You know like you’ll always be a mother but for some
people it’s going to be a short period and learning how to acknowledge that they
are a mom even though their baby may have died or whatever- they have a very,
very, premature delivery. And you know it’s just, I think people if you've had a loss
people don't think of that, you are a mother, you were a mother. Recognizing the
life that was is very important. That's something I learned ... That people still
remember, they want to remember and they want to celebrate the life that was there
even though it ended not the way they intended. (MFM 4)
I think the most difficult [thing] emotionally is when you’re a doctor and you have
these bonds with a family and you feel their struggles in some ways and you feel
really bad for them. It just highlights how unfair [things are]. So, like I had a patient
today who came to the hospital with severe, severe growth restriction, a baby whose
prognosis is abysmal. And she tried 5 IVF cycles and they all failed, you know Like
you think to yourself ugh, how is this—ugh. I think that’s, that’s the worst. (MFM
6)

57

That being said, one sentiment expressed repeatedly by MFMs is the fear they have about
being perceived as coercive by their patients in the context of termination. Many worried
that patients might perceive the professional obligation MFMs felt to offer termination as
an option in instances of severe anomaly as a directive to terminate because of said
anomaly.
You know, the doctor told me I should terminate and that’s not ever my intention,
but that is sometimes all someone can hear when it’s brought up for the first time.
Um, but my hope is that they feel like they have more information than before they
started to help figure out what the best choice is for them and their family. (MFM
14)
In addition to expressing fears around being perceived as coercive, some MFMs expressed
feelings of self-doubt with regards to their own capabilities and how well they were
counseling their patients.
[In some situations] I feel like I must not have explained or counseled well enough
for the patient to have a truly good and logical understanding of the situation.
Because it seems like they’re making decisions that don’t, um, from a perspective
that doesn’t have a good understanding of the consequences. And so then I feel that
I myself am to blame for not providing enough education and counseling for them
to have a true understanding. (MFM 14)
[In reference to a specific case] I think there was also a lot of guilt on my part. Like
did I miss something. So that’s number one, like did I do this family wrong
somehow. You always second guess yourself, that’s what we do as doctors, did I
somehow fail this family? (MFM 6)
4. Physician-Patient Relationship
MFMs discussed how they established positive relationships with their patients in order to
improve the delivery of care. In general, most MFMs described their relationship with their
patient through their communication patterns and the extent to which decision making was
shared between physician and patient. Within this cluster, we identified three themes and
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eight sub-themes to describe the physician-patient relationship in the context of prenatal
diagnosis and decision making.
Effective Communication
MFMs discussed the different communication techniques they employed in order to
maximize the amount of information patients understood during their appointment in order
to further foster the physician-patient relationship. The MFMs we spoke with discussed the
fact that the information they were tasked with explaining to patients was often of a very
high degree of complexity. In general, many felt that the average patient was not prepared
to understand the intricacies of prenatal diagnosis, including the technical aspects of
testing, the meaning of results and the implications of given findings. Consequently, they
felt it was important to try to convert as much information as possible into layman’s terms.
Some MFMs described employing simplifying language, while others relied on numbers,
and some used drawings and images to explain concepts to patients.

In order to ensure they were employing effective communication methods, some MFMs
discussed eliciting patient understanding throughout the counseling session.
I initially have them parrot some of it back to me just so I can make sure that they
have a good understanding. I will ask ‘do you guys have a good understanding
about the outcomes?’ And so throughout the conversation I gauge them on their
level of understanding and if not we might have to go back and revisit it. But when
I am talking it is not like 10 minutes at a time it's usually like snippets here and
there and then gauging their response. I usually ask them if they have any questions
in between. In my mind I still organize it kind of the same way you would with a
dissertation or a speech with an introduction, basic pathophysiology, stuff like that.
[And I] gauge understanding kind of throughout. (MFM 13)
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Responding to Parental Needs
MFMs further described the process of counseling patients as iterative--changing in
response to the needs of the patient in order to ensure they were receiving appropriate
counsel. This was especially the case when patients came to their appointment with a
spouse or other family member. The MFMs we spoke to felt that many women do not
anticipate bad news when bringing family members to their appointments. As such, they
described an obligation to ensure the patient was comfortable with family being around to
hear bad news before conveying it.
The patient is really our patient right so I feel that firstly she has to be the one that
allows everybody else to be in the room and participate in the counselling and so
if that is not something that she is okay with, then we will politely ask for everyone
to leave. (MFM 12)
Moreover, MFMs felt it was important that the patient feel they were dictating the type of
care they received as opposed to feeling like the MFM was forcing something (either a test
or an intervention) on them. To that end, MFMs felt it was important to only offer patients
further testing if patients felt they would act upon that information. If a patient did not feel
that a screen or test would change their management, MFMs did not feel it was appropriate
to offer it to them.
Ultimately the way I counsel patients regarding this is...the right answer is
whatever you want to do. You need to want the information because if you don't
want the information and it's not going to change anything then there really isn't a
good reason to do the test. We can do a [screening] ultrasound for you, but we're
doing this screening test and we’re screening for Down Syndrome--this test could
come back positive for Down Syndrome or it might not. I always say there are three
different types of people: there's somebody who would say you know what I
absolutely need to know because it would completely change things that I do. I say
if that is you that’s the right answer for you and we will proceed with things. There
are people who say you know it wouldn't change anything that I would do but I
would just like to be informed to know so that I can plan accordingly. Also the right
answer if that’s your choice. And then somebody else might say “I don't really need
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to know I don't want to know if not going to change anything,” then you probably
should not have this test done. (MFM 2)
As has already been touched upon, many MFMs described the process of offering
termination to patients as being a charged topic. That being said, all MFMs we spoke to
felt that they needed to bring up the option of termination at least once during their
discussions with their patients. In order to do this, many MFMs utilized a technique we
dubbed as “Reactive Values Elicitation,” wherein they broach the topic of termination with
their patients and, pending their patient’s reaction, either continue to discuss termination
as an option or abandon discussions of termination all together.
You tell them [termination is an option], and if they get upset, you know their
values. (MFM 15)
So, it’s obviously very gentle, because you have to sort of get a sense for who the
patient is. And usually the patient is the one, it’ll be pretty obvious, usually pretty
clear if termination if termination is something she’s considering or if it’s off the
table. (MFM 16)
Shared Decision-Making
While MFMs avoided prescriptive counseling, many felt that patients needed their help in
determining what decision was best for them. In order to assist patients in reaching their
ultimate decision, MFMs described themselves as guides.
I just try to do what I can for the patient. Sometimes it’s asking slightly guided
questions like, would you want to hold the baby, would you want to see with your
own eyes what it is that I’m seeing on ultrasound, would you want pictures? (MFM
4)
Most people don’t really know what to do and they’re looking for some guidance
as well. It’s a really tight balance...And so, I would say it’s hard to give hard and
fast rules because a lot of it depends on the conversation at the time and the woman
and her partner and what’s going on in the room so you get a sense. (MFM 16)
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When discussing their role in the shared-decision making paradigm, all MFMs viewed
themselves as informants. In order words, MFMs felt their main role was to ensure patients
had all the information necessary in order to make an educated decision regarding the
course of their pregnancy.

One consideration some MFMs felt was important to bring to patients is the maternal risk
associated with pregnancy. They felt this was an important consideration especially in the
instances where women are carrying fetuses with lethal anomalies, as some MFMs felt that
if there was no chance of meaningful survival of a fetus, the maternal risk to carrying the
pregnancy to term might outweigh the patient’s desire to carry their fetus to term.

5. Patient’s Experience
MFMs defined their perceptions of the patient’s experience while undergoing prenatal
counseling according to factors they believed to influence patient decisions and the
patient’s emotional response to news received throughout the diagnostic process. These
factors framed how patients understood the information given to them by their MFMs, and
their decision making process. Within this cluster, we identified five themes and six subthemes.
Cultural Influence
MFMs identified varying aspects of a given patient’s culture as impactful in their decision
making process. These ranged from their heritage, their faith and the language they spoke.
MFMs identified these factors as intersecting to different degrees in order to influence a
patient’s ultimate decision regarding termination of their pregnancy.
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In general, MFMs felt that religious patients were less likely to consider termination. They
spoke of individuals from all major monotheistic religions--Christianity, Islam and
Judaism--when illustrating this point. MFMs felt that these patients leveraged their
religious beliefs and leaders when deciding how to approach a diagnosis of fetal anomaly.
While most felt faith had a positive effect on patient coping and decision making, one MFM
spoke of a time where a patient began to question their faith in response to a diagnosis of
lethal anomaly.
I can think of a couple, but probably the one that sticks out most in my mind is I
had a patient [...] I don’t remember exactly what the diagnosis was, but it was a
patient who had a fetus that had some significant structural anomalies and I think
had hydrops as well, and she in the mid-trimester was diagnosed with hydrops, her
husband was a preacher. A Baptist minister. And you know, they really didn’t want
to accept what was going on. And they came once and they said, “well we think
everything’s going to be ok.” And we said, “so come back in a few weeks and we’ll
reassess.” They came back in a few weeks, and we told them “no, nothing was any
better, there were still significant problems there.” And he refused to accept it, he
became belligerent, started screaming at the staff, punching the walls, and things
like that […] I think it’s because for him, his faith was challenged. And you know,
it made him question what he had believed in. So, it was much easier to lash out at
the care team than it was for him to sort of accept the reality. (MFM 5)
Familial Influence
As previously touched upon, women often come into a counseling session with family in
tow. MFMs discussed the influence they thought families had on a patient’s ultimate
decision regarding termination of a pregnancy. Thoughts were divided into positive and
negative categories. On the one hand, MFMs identified the support a family can provide
emotionally as being incredibly helpful for women considering termination of a pregnancy.
Moreover, they identified familial support as being instrumental for those women deciding
to keep a pregnancy with diagnosed anomaly. However, some MFMs felt that friends and
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families can be a source of stress for patients who are ashamed about a diagnosed anomaly
or the choice to terminate.
I would also throw in for those that are leaning towards termination, I tell them
listen, a lot of people probably know you’re pregnant, and if you decide to end the
pregnancy, what you should tell them is I lost the baby. It’s a true statement and
it’s vague enough that it covers a lot of potential, and it’s also...um...a respect my
privacy type statement. I tell them you can tell more to people who you want to tell,
but it will shut up most people if you just say I lost the baby. Say ‘I don’t want to
talk about it.’ And I say the reason it’s true is because you’ve lost the baby you
were dreaming about. This baby is not what you were dreaming about, and that
pregnancy is not - it’s lost. (MFM 3)
So I’d still say probably his or her family more than anyone else. Or what I have
seen especially with people with strong social support, they rely very heavily on
their family background. And have pretty in-depth discussions to the point where
family members sometimes take over those discussions. I think we- our job is to
provide them with the tools to make this decision. Then it is the family and the
patient that ultimately has the long-term outcomes so hopefully they make it as a
group. (MFM 13)
Barriers to Care
Throughout our discussions, many MFMs lamented the extent to which financial
considerations impacted their patient’s ultimate decision. Whether patients were interested
in genetic testing, termination, or continuing a pregnancy, MFMs noted that they were
limited by the costs of the testing they could receive, whether or not they could afford an
abortion, and their ability to support a medically involved child. One MFM commented on
the cruelty of a medical system that forces patients to pay out of pocket for termination and
saddles them with the costs of labor and delivery in the event that they continue a pregnancy
for a fetus with a lethal condition.
We have [the ability to offer patients terminations] but it's all out of pocket pay
[...] Like we [also] have Planned Parenthood here who will do terminations after
20 weeks but once again that's not free of cost.
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[Later, when discussing a fetus with anencephaly] I didn’t bill a professional fee
for delivery because I think that’s rude, but they’ll get the same bill [from the
hospital] that they would have if they had a baby they got to go home with. (MFM
2)
Moreover, MFMs identified two major areas where insurance coverage for their patients is
lacking. One is insurance coverage for genetic testing and other advanced methods of
prenatal diagnosis. The other was for termination.
I mean I offer all the patients amniocentesis for you know, obviously the early
enough CVS, karyotype, and microarray. If there are certain things that I feel like
I should narrow the testing down to. Would offer specific genetic, you know,
mutation analysis for a specific disorder. The fact of the matter is, being down here
and what I mean here really overall in the south. Insurance coverage for some of
the more comprehensive testing like whole exome um and even some of the panel
testing is not well covered. (MFM 5)
They frequently want to have the termination in the hospital, paid for by their
insurance. And when I inform them that they can’t have it done in the hospital, and
their insurance may or may not pay for it, depending on their insurance, they get
really angry. Because in their mind it’s not an abortion, and it’s not something
they’d ever do, it’s extenuating circumstances. (MFM 8)
In addition to financial barriers, many MFMs lamented the restrictions placed on them by
their institutions when providing prenatal counseling to a woman with anomaly. This was
especially discussed in the context of termination. MFMs discussed limitations their
institution placed on them either regarding the extent to which they discuss termination
with their patients, or their ability to offer patients termination in house.
We’re limited by practice in a federal hospital where by law we’re not allowed to
perform a termination unless it’s rape, incest, or life of the mother, so regardless
of a genetic diagnosis, it’s something that I would have to refer them to a civilian
provider, but I do bring that up with them. (MFM 17)
So, we don’t have a full spectrum of options available to carry out with the patient.
We’re a Catholic non-profit facility. But we do talk to patients about everything
from treatment if its amenable to treatment all the way to abortions. [...]But we
actually have to…[they don’t allow us to] hand out resources around that, they
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have to actually just take down the phone number we give them [...] We had a
handout that we used to give our patients, on available various, variable places to
terminate and resources around that. But then Catholic health said that they
wouldn’t allow that. They said we’d be ok if we had them write down the number
or the name. Kind of a silly thing but they don’t want it to be publicized that we’re
necessarily promoting that, so we have to kind of navigate within the system to give
the patient all their options. We still do, but it’s kind of weird, I guess. (MFM 11)
Emotional Response
When discussing patient reactions to a prenatal diagnosis of anomaly, many MFMs
highlighted the sense of hope patients maintain surrounding the diagnosis. Specifically,
MFMs noted that many patients maintained a hope that their baby’s condition was not as
bad as predicted based on the diagnosis given by the MFM.
I think it could be good and I think there’s always that chance that you’re going to
have the miracle baby. Going to have a reality show and everything is going to be
happy. and I think that's what these patients are looking out for it I think the chance
of that happening is less than 1% but it's not zero. and everybody hopes for that.
(MFM 1)
[Patient’s think] “that won’t happen to my kid” (MFM 7)
I don't want to take away hope you know if there is reason for hope I will never take
that away and often times patients will say “well you know I pray to God that
everything will be fine” and that is good. that is fine. I encourage that but it does
not take away what I see, and I can share that with them. (MFM 12)
While prior to the birth of their child, many patients hope for a different outcome, MFMs
discussed instances where patients expressed regret at continuing a pregnancy after
realizing the extent of complications their child faced.
I don't know what it is like from the child’s perspective. I definitely see it from the
parent perspective and it once again a variety of outcomes. I have heard families
tell me before if they had to do it again they would not have done it again 6 years10 years out [...] For some people [continuing a pregnancy] is the right decision
and for other ppl they feel external pressures that make them decide [to continue
the pregnancy] and [later the way they feel about it] may manifest as regret. (MFM
13)
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Inability to Understand Child’s Condition
MFMs identified many instances where they felt that their patient was unable to understand
a given diagnosis of anomaly in their fetus. Some MFMs felt that their patients lacked the
background knowledge to understand the basis of genetic testing in general, much less the
diagnosis of an anomaly. This discrepancy in patient education level made it extremely
difficult for patients to make informed decisions surrounding their pregnancy because
MFMs felt they were not prepared to understand their child’s condition at baseline.
That's probably the hardest part in some ways because the vast majority of
Americans actually have pretty poor literacy and medical understanding. So there
are a lot of people I’m explaining what a chromosome is – they don’t understand
that you get a set from your mom a set from your dad. So I use colloquialisms or
other terms like for example for like the karyotype or the chromosomes I use the
word like blueprint or-“this is the, you know, instructions that tells the cell to do
what it needs to do” – and that's something that comes with years of doing it. And
like observing senior faculty or your senior resident, your senior fellow counsel
patients and you pick up on these little terminologies that you can use to convert
complex medical concepts to layman’s terms. So yeah I think that's one of the hard
parts. (MFM 4)
Some MFMs expressed concerns that patients who spoke another language had difficulties
understanding their fetus’ diagnosis even in the setting of interpreters. As one MFM
described:
With a language barrier all these difficulties and these grey areas become so much
more complicated to communicate. (MFM 12)

6. Termination
A large part of our discussions with MFMs revolved around the termination of pregnancies
in the context of an unfavorable prenatal diagnosis. As has been mentioned repeatedly
throughout our results thus far, all MFMs offered the option of termination to all of their
patients, and offered additional counseling on the matter if patients requested. That being
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said, we identified three unique themes during our discussions on termination that we felt
warranted additional exploration.
Abortion Culture
Many MFMs referenced the overall “abortion culture” of their patient population. We took
this to reference the likelihood that patients in their population would strongly consider the
option of termination or proceed with a termination in the event of a prenatal diagnosis of
congenital anomaly. Per our MFMs, abortion culture varied regionally.
Most of the time with an abnormal diagnosis, because I practice in NYC where
people terminate pregnancies, it’s not that unusual. (MFM 16)
I think that because termination, pregnancy termination rates are so low in the
south for genetic anomalies… (MFM 5)
[In the mid-west] they just don't accept it, like, here politically there's tons of
barriers to termination in this state, it's very challenging to do that here, so I think
there's definitely a political trickle-down for this that that's not an acceptable
option in pregnancy, so I think it's a combination of the both of them but I almost
think it is more political than religious. (MFM 2)
Abortion Tourism
An interesting topic mentioned by many MFMs was that of ‘Abortion Tourism.’ As has
already been discussed, many MFMs are limited in their ability to offer patients
terminations due to institutional or regional laws restricting abortion access. Consequently,
many MFMs counsel their patients that they have the option to travel out of state to get the
care that they need. On the flip side, MFMs who practice in areas with fewer restrictions
surrounding abortion discussed the abortion tourism from the perspective of receiving an
influx of patients seeking terminations from out of state.
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Legal Considerations
Finally, many MFMs brought up the fact that they had to counsel their patients on the legal
considerations surrounding pregnancy termination. This was usually in reference to the
gestational age limitations for abortion, which varied from state to state.
I just tell them up to state law, termination is up to 23 weeks and 6 days that's the
law if you’re considering that let us know we’ll get you hooked up with the
resources and they kind of leave it at that. If someone is coming to us a little bit
later, they've missed the cut off. Then I try and hook them up with the correct
resources that would still be viable but those are really few and far between.
(MFM 4)
Some MFMs discussed recent implementations of laws in their state surrounding the
termination of a fetus with a known diagnosis of Trisomy 21. In these instances, patients
could get a termination if they were at a gestational age before the designated cut off in
their state for any reason, unless it was discovered that the patient’s fetus carried a diagnosis
of Trisomy 21.

DISCUSSION
This study is an exploratory qualitative analysis meant to shed light on the experiences of
MFMs who sit at the forefront of prenatal genetic screening and diagnosis. Our goal was
to gain a better understanding of key attitudes and opinions of MFMs surrounding prenatal
genetic testing, disability and termination. The perspectives and experiences of these
MFMs provide insight on the pitfalls surrounding our current prenatal screening, diagnostic
testing and counseling paradigm, and help us identify areas of needed improvement in
order to ensure patients are informed enough to make autonomous decisions regarding the
course of their pregnancy, and thus achieve the aim of prenatal consultation as set forth by
ACOG. This is of great significance as, while MFMs are not the sole responsible actors in
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ensuring these criteria are met for patients, they do hold an important obligation given that
they are often either the first provider to discuss prenatal genetic screening and diagnostic
options with a patient, or the first to explain the results of a screening test to a patient28.
To that end, we identified six thematic clusters that characterize how MFM providers in
the US conceptualize prenatal consultations of women with a finding of a fetal anomaly.
Each cluster has important impacts on the three major requirements of informed consent
set forth by Beauchamp and Childress in their “Principles of Biomedical Ethics.” They are
as follows: 1) Patients should be given access to high quality, accurate information about
the technology of the testing modality in question and their results; 2) Patients should be
given information surrounding life with any of the anomalies being screened for, and
implications of a positive result; and 3) Patients should be given both adequate access to
prenatal testing and adequate time to discuss prenatal testing with their providers in order
to ensure full understanding. Here, we discuss the potential extent to which our findings
reflect fulfillment and barriers to fulfillment of these requirements.

Methodological Barriers to Care
As referral providers, MFMs were often not the first to discuss or administer prenatal
genetic screening tests to a patient. However, they were often the first to explain the results
to a patient referred to them for findings of likely anomaly. In these instances, MFMs found
that inconsistencies in practice between themselves and referral providers served as a major
barrier to educating patients on the tests they received and the implications of their results.
As a result, MFMs felt that patients had not made informed decisions regarding prenatal
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screening, thereby highlighting concerns of routinization of prenatal screening identified
in other studies41-43.

Beyond inconsistencies in practice between MFMs and referral providers, some MFMs
identified inconsistencies in practice between themselves and the other MFMs they worked
with. These inconsistencies in practice led to patients receiving mixed messages about their
options for prenatal diagnosis and the implications of their results. It was unclear if these
inconsistencies were a consequence of personal bias or a lack of an established
standardized approach to counseling from professional bodies. Addressing the
methodological pitfalls raised by MFMs in our study could help improve patient and
provider experiences with prenatal consultations through improvement in referral systems
and establishing practice guidelines within physician groups.

Providing Sufficient Patient Education on Testing Modalities and Results: Straining
the Physician-Patient Relationship
Another major challenge in discussing testing modalities with patients came when trying
to explain unclear results. In these instances, MFMs expressed difficulties communicating
to patients that there is no way of knowing whether the genetic finding in question would
lead to some sort of pathology in their fetus or not. These findings of unclear significance
force patients and providers to grapple with uncertainty when trying to make decisions
regarding pregnancy continuation.

This uncertainty was further reflected in the diagnosis of known genetically anomalous
conditions, like Trisomy 21, where there exists a significant spectrum of outcomes. Indeed,
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within Trisomy 21, some children may present as higher functioning than others. The same
is true for many other diagnosable genetic anomalies. And yet, patients often seek a clear
picture of what exactly to expect when raising a child with an identified genetic anomaly,
which MFMs felt unable to provide. Consequently, many MFMs described a sense that the
technology available to patients for screening and diagnosing congenital anomaly has far
outpaced our understanding of anomaly. This gap in knowledge was identified as a barrier
to ensuring patients were making fully informed decisions regarding the course of their
pregnancy following a diagnosis of genetic anomaly.

To minimize the ambiguity of genetic findings, MFMs described a number of approaches
to ensure patients were appropriately informed about the tests they could receive and the
implications of a positive or negative test result. They described creating a set of standard,
internal goals for each counseling session in order to ensure they were administering as
much information to patients as possible. Moreover, when establishing a diagnosis of
anomaly in a fetus, MFMs did not solely rely on genetic results, but discussed using a
multifaceted approach that combined imaging with genetic testing to provide patients with
more information regarding their pregnancy.

That being said, many MFMs identified a lack of insurance coverage for certain genetic
tests as being a barrier to providing patients with as much information about their
pregnancy as possible before making decisions regarding management. Indeed, financing
of genetic screening and diagnostic tests is complex and variable. And while our current
practice model encourages the provision of as much information to patients as possible in
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order to ensure informed decision making, not all patients have equal access to the testing
modalities needed to make fully informed decisions. Thus, inadequate insurance coverage
of prenatal genetic testing may make it difficult for patients to fully understand the
implications of a given screening result.

Thus, while many MFMs discussed personal strategies to overcome barriers to educating
patients on prenatal genetic testing, our findings highlight the fact that our current testing
paradigm cannot provide patients with absolute answers regarding the implications of a
positive genetic finding. This is because limitations in our current technology preclude
MFMs from giving patients definite answers on the implications of their results.
Inconsistencies in referring obstetric provider understanding of genetic testing and
screening modalities compound this ambiguity, and make it more difficult for patients to
be informed on issues of prenatal screening, diagnosis, and management. Moreover,
variable insurance coverage of prenatal genetic testing means that not all patients receive
the same amount of information before having to make decisions about their pregnancy
course. Ensuring baseline patient and provider education through a universal approach,
which can be published by ACOG or SMFM, and ensuring universal coverage of genetic
screening and testing for all patients could be ways to act upon our findings.

Implications of a Positive Screen: Lack of Meaningful and Consistent Discussions on
Life with Disability
Because the genetic conditions most commonly screened for by current prenatal screening
modalities result in some level of disability in the neonate, MFMs are often tasked with
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explaining the implications of said disability on the neonate’s quality of life. Of course, the
term ‘disability’ encompasses a broad number of conditions despite often being referred to
as a monolith. Consequently, it was unsurprising that each MFM we spoke with conceived
of disability in a different way. While almost all MFMs described disability along a
spectrum, the endpoints of each spectrum varied, with some MFMs thinking of disability
in terms of major and minor conditions, others in terms of perceived quality of life, and so
on. There was no standardized criteria MFMs used when classifying a condition as a major
or minor disability. Most relied on gestalt.

This lack of standardization was of particular importance when discussing what MFMs
considered to be “major disabilities,” “severe disabilities,” or “lethal conditions,” as MFMs
felt obligated to initiate discussions about termination in the setting of both severe and
lethal congenital anomalies. We found this lack of standardization regarding definitions of
disability, disability severity and lethality incredibly interesting in the setting of the fear of
being perceived by patients as encouraging termination that many MFMs described.
Indeed, it is possible that the varying thresholds among MFMs for discussing termination
with their patients might contribute to the documented patient perception of providers
encouraging termination in the setting of a prenatal diagnosis of anomaly35.

Beyond having varying definitions of disability severity and lethality, many MFMs
described a complete lack of understanding of what it meant to be disabled, and to live with
and care for a child with a disability. Consequently, many struggled to provide this
information to patients when prompted. However, the majority of MFMs we spoke to
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described good relationships with Pediatricians who they could refer their patients to in
order to provide them with information on life with a disability.

To our knowledge, our findings of a lack of a standardized approach for discussions of
disability severity and termination are the first of their kind. Moreover, they highlight the
need for professional bodies to establish guidelines for MFMs to follow when initiating
conversations about termination in the setting of congenital anomaly. Without the
establishment of a standardized approach to these discussions, it is impossible to evaluate
whether or not patients are making truly informed decisions regarding termination in the
setting of a prenatal genetic diagnosis.

Focus on the Patient Experience: Ensuring Patient Understanding of Screening
Results
The final criteria of informed consent is ensuring patients “understand at least what a health
care professional...believes a patient...needs to understand in order to authorize
intervention”14. In order to ensure patient understanding of prenatal screening and testing
modalities, as well as the implications of a given result, MFMs discussed a myriad of tactics
they employed in their practice. These included adopting a standardized/consistent
approach to patient counseling and engaging in repetitive counseling as much as possible.
For many, this meant scheduling multiple follow up appointments with patients in order to
give them time to think about the information received, and to come up with additional
questions to discuss at subsequent visits.
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That being said, MFMs described the lack of time they are afforded to devote adequate
attention to counseling patients on their options and results as a major barrier to ensuring
patient understanding. This barrier has been previously documented in the literature,
highlighting the fact that MFMs do not feel that they are given sufficient time to thoroughly
educate patients on issues related to prenatal genetic testing26. These findings highlight the
need to identify ways in which time allotted to prenatal counseling sessions can be
expanded. Possibilities include the expansion of insurance coverage for longer counseling
sessions or through more widespread involvement of genetic counselors who can offload
the burden of counseling placed on MFMs.

Restrictions on Termination also Restrict Discussing Termination
Within the context of this study, we chose to focus on informed consent as the basis for the
Reproductive Autonomy Rationale. And while inadequate understanding serves as a direct
barrier to meaningful choice, the meaning of personal autonomy extends beyond this to
include the ability to make choices free from controlling interference52. And while the
MFMs we spoke with did everything in their power to ensure patients were able to make
autonomous decisions by providing them with as much information as possible, many
described institutional restrictions surrounding discussions of pregnancy termination and
legal barriers to access termination services. Consequently, some MFMs reported the
inability to engage in open conversations surrounding pregnancy termination because the
institution they practiced under prevented them from doing so.

With regards to legal barriers to accessing termination services, many MFMs described
instances where patients received diagnosis of lethal congenital anomaly at a gestational
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age after a given state’s cut off for termination. Consequently, those patients could not
choose to terminate even if pregnancy termination was felt to be in the patient’s best
interest. Moreover, because many insurance providers do not cover termination costs, if
patients could not afford to pay for a pregnancy termination out of pocket, the choice to
terminate a pregnancy was lost to them. This highlights a concerning disparity in terms of
access underscores the need for universal access with coverage for all necessary medical
procedures, including pregnancy termination.

Understanding the MFM Experience: Informationally engaged, morally detached
Throughout our discussions, we asked MFMs questions regarding their feelings on the role
they play throughout the process of prenatal counseling. MFMs predominantly described
themselves as guides for patients navigating the process of prenatal diagnosis, helping to
provide patients with the information and resources they needed to make decisions
regarding the course of their pregnancy. Interestingly, in order to fill this role as a nonjudgmental and unbiased informant, MFMs expressed a sense of role morality. This meant
that MFMs felt that their role as an MFM excused them from abiding by their own personal
moral reasoning to support the moral decision making of their patients. As a result, in an
attempt to remain as unbiased and non-judgmental as possible, many MFMs expressed
feelings of moral distress when discussing times where patients made decisions that the
MFM did not agree with regarding the course of their pregnancy. Perhaps to alleviate this
discomfort, many MFMs attempted to distance themselves from a patient’s ultimate
decision by refusing to answer patients when asked “What would you [the MFM] do if you
were in my shoes?” These responses highlight the efforts made by MFMs to provide
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unbiased care to their patients by separating their personal opinions from their professional
ones.

Strengths and Limitations
This qualitative study utilized a grounded theory approach to thematic analysis of openended semi-structured interviews with MFM providers across the United States. This
approach allowed us to identify robust and novel themes to characterize how MFM
perceptions of prenatal genetic testing, disability, and termination might influence patient
reproductive autonomy. However, there are several strengths and limitations to this study
that present opportunities for future investigation.

In using an open-ended and semi-structured approach to interviewing MFMs, we allowed
for providers to identify topics they felt were most important when discussing issues of
prenatal genetic diagnosis, disability and termination. However, in recruiting participants
using the snowball method, we may have limited the variety of perspectives explored in
this study by only speaking to providers from a similar social network. Moreover, because
the majority of providers we spoke to practiced in major academic centers, the perspectives
of private practitioners and practitioners in rural settings is missing from our work.
Additionally, this sample is ultimately composed of MFMs who were willing to participate
and discuss their experience, which might result in responder bias. Finally, the mix of
professional backgrounds within the research team promoted a consideration of a variety
of interpretations after thorough scrutiny of data. However, we did not include a general
OBGYN or Primary Care Physician (PCP) in our team. As providers who often refer
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patients to MFMs, the perspective of an OBGYN or PCP may have been useful in the
analysis of MFM discussions on their role as referral providers.

Conclusions and Future Directions
As the technology behind prenatal genetic screening and diagnosis continues to expand, it
is imperative that we understand how the application of these technologies impacts a
patient’s ability to make autonomous choices regarding the course of their pregnancy.
While in many instances information gleaned from prenatal genetic testing can positively
influence patient care, the clinical trends and ethical concerns identified in this study
indicate there is room for significant improvement regarding counseling, informed
decision-making and access to care.

While providers supported the use of prenatal genetic screening and diagnostic tests,
significant issues emerged at the frontline of integration of these tests into clinical practice.
These include: 1) Minimal patient education on screening tests by referring providers; 2)
Inconsistencies in practice among administering providers; 3) Limitations in our current
screening and diagnostic technology that prevents us from helping patients to understand
the implications of a diagnosis; and 4) Variable insurance coverage for more
comprehensive genetic testing.

Moreover, here we discussed the novel finding of a lack of standardization of provider
understanding of disability, disability severity, and lethality. Because these definitions
often serve to frame discussions of termination between patient and provider, it is
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imperative that professional bodies establish standardized definitions of these concepts in
order to ensure uniformity of patient care and informed consent.

That being said, providers highlighted serious structural barriers to ensuring informed
consent and autonomous decision making among patients. These include inadequate time
to explain screening and testing options, and limited access to abortion services. Unless
both are addressed, it is difficult to imagine a way in which all patients can make truly
autonomous decisions regarding the course of their pregnancy following a prenatal
diagnosis of genetic anomaly. It is imperative that women carrying fetuses with similar
diagnosis have access to equal quality of care.

As the technology surrounding prenatal screening and diagnosis continues to evolve, so
must the informed consent process and the resources available to patients making
decisions. Addressing the ethical issues discussed above can help MFMs maximize the
advantages of prenatal genetic testing for patients and minimize barriers to reproductive
autonomy. We hope this study serves as the foundation for future studies aimed at
establishing more comprehensive guidelines for MFMs to rely on when discussing issues
related to disability and termination with patients, with the ultimate goal of ensuring more
equitable healthcare outcomes for women undergoing prenatal consultation for fetal
anomalies.
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